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Temperate phages are capable of both lytic and lysogenic growth. In lytic growth, phages 
utilize the host machinery to produce new virions and kill their host; during lysogeny, the phage 
genome integrates into the host chromosome and produces a repressor that prevents expression 
of lytic genes, thus maintaining the lysogenic state. A few phage genetic switches governing the 
lytic/lysogenic decision have been well characterized, most of which contain analogous 
regulatory proteins with similar functions. A new type of genetic switch, which uses phage 
integration directly in synthesizing the phage repressor, is described. This dependence on 
integration arises because of the unusual feature that the attP core, the site where strand 
exchange occurs during integration, is located within the repressor gene; in this study we are 
using the mycobacteriophage BPs as a model system.  The BPs repressor gene, 33, encodes a 
136-residue protein (gp33136) that we have shown is not active for immunity unless 
overexpressed.  However, when the phage genome integrates into the bacterial chromosome, a 
stop codon is introduced at the attL junction site, creating a truncated, but active form of the 
repressor (gp33103), which is expressed within the lysogen.  Electrophoretic mobility shift assays 
(EMSA) have shown that each form of the repressor binds specifically to two operators present 
within the 33-34 intergenic regulatory region, as well as to four other operators located across the 
BPs genome.  Here we report studies done to map the sequence requirements for repressor 
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function in repressing lytic growth and show that a previously reported 12 bp operator sequence 
represents one half of a full binding site.  We also show that the BPs repressor does not seem to 
form inter-DNA bridges for transcriptional regulation, but evidence suggests that bending DNA 
plays a role.  Characterization of the binding sites and behavior of the BPs repressor will deepen 
our understanding of this new class of integrations-dependent switch.  The overarching goal, of 
which this project represents only a portion, is to dissect BPs so that we have a full 
understanding of its biology, what its genes do, how they are expressed, how expression is 
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1.0  INTRODUCTION 
Bacteriophages can be manipulated and used in a variety of ways related to molecular biology, 
for example as tools for genetic study.  Mycobacteriophages, the phages of mycobacteria, have 
been instrumental in the development of tools for the manipulation of the Mycobacterium 
tuberculosis genome (1-18).  Mycobacteriophages have already been used to develop a 
mycobacterial site-specific recombination system (15-18), transposon and reporter gene delivery 
systems (1, 2, 19), selectable markers (3, 20), stable integration-proficient vectors (6-8) and for 
the creation of recombinant bacterial vaccines (4).  With over 850 sequenced mycobacteriophage 
genomes (www.phagesdb.org) showing a remarkable variety of novel genes, there is significant 
potential for discovering more genes that will have an impact on the study of M. tuberculosis 
pathogenesis (5, 21, 22). 
In order to harness the power of mycobacteriophage genetics, it is important to 
understand how these viruses control gene expression.  A classic example is when a temperate 
phage makes the decision to enter either lytic or lysogenic growth, a process governed by a 
genetic switch, which activates or represses relevant genes (12, 23). By studying and 
understanding these pathways we will get, not only a deeper understanding of how phages 
function and interact with their hosts, but also insights into how biological switches are regulated 
by different genetic components.     
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1.1 WHY STUDY MYCOBACTERIOPHAGES? 
Mycobacterium tuberculosis is a major human pathogen affecting one in every three people 
across the world (24-26).  It causes the disease tuberculosis, which, if left untreated, constitutes a 
potentially deadly respiratory infection.  Treatment for tuberculosis is costly and time-consuming 
(27).  When a patient is diagnosed with tuberculosis, they are treated using a combination of 
drugs (28).  Since most of the infection is cleared away and symptoms of the disease disappear 
quickly after drug treatment begins, patients occasionally cease to continue taking their drugs, 
allowing the remaining M. tuberculosis to proliferate, providing an opportunity for multi (MDR) 
and extremely (XDR) drug-resistant strains to emerge (29, 30).  Drug-resistant strains are a 
major cause of death in citizens of developing countries across the world (29, 31). They are 
especially disastrous in patients with Acquired Immunodeficiency Syndrome (AIDS), because 
immunocompromised patients are unable to fight off infection or keep the infection at bay, thus 
making the problem of drug-resistance larger (28, 32).   
With the emergence of drug-resistant and multi-drug resistant strains of bacteria, the 
future of antibiotics has come into question and the therapeutic potential of bacteriophages, 
viruses that infect bacteria, is being explored (33).  Phages can be manipulated and used in a 
variety of ways, including as tools for genetic study and as new technology for treatment of 
bacterial infections.  Already, the development of bacteriophages as cloning vectors and 
transporters of recombinant DNA has revolutionized the field of molecular microbiology.  The 
clinical prospects of phages are also numerous and these viruses are already being used in some 
parts of the world as part of primary treatment methods for chronic and drug resistant bacterial 
infections, as well as in disease prevention. (33-37) Phages also encode proteins with 
antimicrobial properties, such as lysins, lysterases, and toxin-encoding genes that are only just 
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beginning to be understood and used as therapeutic agents (38-40).  Additionally, phage capsids 
are being used to display epitopes that help immunize against certain cancers (41-44).   
Since mycobacteriophages infect mycobacteria such as M. tuberculosis, the expanding 
database of fully sequenced phage genomes provide a great body of data to explore for 
therapeutic potential against the etiological agent of tuberculosis. 
1.2 GENETIC SWITCHES CONTROLLING TEMPERATE PHAGE LIFECYCLES 
A bacterium infected by a temperate bacteriophage will have one of two fates: death due to lytic 
growth or latent infection during lysogeny (12, 45).  If environmental conditions are optimal for 
bacterial growth, the infecting bacteriophage will replicate its genome and assemble new virions, 
then lyse the bacterium to release infectious progeny phage. If environmental conditions are not 
optimal, or if there is a high concentration of infecting phages, an infecting bacteriophage will 
integrate its genome into the bacterial chromosome, becoming a prophage. The prophage 
expresses a repressor protein to shut off expression of lytic genes and keep its genome integrated. 
The presence of repressor also prevents lytic infection from other phages that use similar 
mechanisms of genetic regulation, thereby conferring immunity to the prophage-containing 
bacterium, or lysogen. (46, 47)  In certain environmental conditions, such as those that cause 
DNA damage, the SOS pathway leads to induction of lytic growth, prophage excision, and 
release of infectious virions into the extracellular environment. This process is known as 
lysogenic induction (45, 48).   
The regulatory elements governing the initiation and stability of these phage life cycles 
make up a bistable genetic switch (23).  The most important attribute of a genetic switch is that 
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once activated, the subsequent series of events will commit the organism to that specific 
pathway. In the context of this project, the phage is dedicated to either lytic or lysogenic growth.  
Phages are the most abundant genetic entities on the planet (49) and due to their genetic 
diversity and prevalence of the temperate phage life cycle being high (50), phages likely have the 
largest reservoir of genetic switches.  The central components that allow commitment to each 
state (51, 52) are likely common in all these switches, but differences arise in how the phages 
flip the switch and maintain it in each state.   
A few phage genetic switches have been characterized thus far, the most well-studied 
being that of bacteriophage lambda (45, 47).  Most of these systems contain analogous regulatory 
proteins with similar functions.  Only a few genetic switches have been characterized in 
mycobacteriophages.  
1.2.1 Bacteriophage Lambda 
The lambda genetic switch is the most well studied phage switch. The genetic switch is complex 
and involves many components located throughout the lambda genome but has one goal, the 
decision and commitment to lytic or lysogenic growth (47).   
To begin infection, bacteriophage lambda absorbs to an Escherichia coli cell and injects 
its genome into the cell. Host RNA polymerase initiates expression from two promoters, PR, 
which transcribes rightwards genes, and PL for leftwards expression. Cro, produced by the PR 
transcript, binds to the PRM promoter and prevents the expression of the repressor, cI (53-55).  
The N gene is transcribed from PL and the N protein is an anti-termination factor that blocks 
transcription termination at the terminator (tR1 and tR2) sites and extends the operons expressed 
from both PL and PR (45).  The anti-terminated PL transcript expresses a number of genes 
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including two that participate in the genetic switch, cIII and int (56).  From promoter PR, the 
genes cII and Q are transcribed when termination at the tR1 site in cro is prevented. Q is also an 
anti-termination factor and the PR’ promoter region contains a qut (Q utilization) site (57).  When 
Q is present, PR’ transcribes the genes for lysis of the host cell and the genes for structural 
proteins that are used to assemble progeny phage. If these conditions persist, lytic growth of the 
bacteriophage will result. Continued synthesis of Cro, an essential lytic regulator, represses the 
PRM promoter by its particular binding pattern at its operators and prevents the transcription of cI 
(47).    
In order for lysogeny to occur, the CII protein must accumulate and activate the PRE 
promoter, which will transcribe the repressor gene, cI. Under conditions that favor lytic growth, 
the cII gene is transcribed from the N-anti-terminated PR transcript but the CII protein is 
susceptible to host protease, FtsH, and is rapidly degraded (58-61).  Without CII, the repressor, 
cI, is not expressed as the PRE promoter is not activated and the PRM promoter is repressed by 
Cro. However, during conditions that favor lysogeny, concentrations of FtsH and other proteases 
are low and CII is able to escape degradation. This is also due to the actions of CIII, which binds 
and sequesters FtsH, and therefore reduces the amount of active FtsH able to degrade CII (62, 
63).  CII is able to act at several promoters and flip the switch towards lysogeny. CII binds to the 
PI promoter and increases expression of the lambda Integrase, which integrates the phage 
genome into the host chromosome at the attP site, creating a prophage (47).  Also, it regulates 
the Pantiq promoter. This leftwards promoter transcribes an antisense transcript of the Q anti-
terminator gene, which is necessary for transcription of lytic genes, and switches off production 
of Q (56).  Finally, CII activates the PRE promoter, which transcribes the cI gene without the 
interference of Cro, which is blocking transcription from PRM (45).  As CI protein begins to 
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accumulate, it competes with Cro for operator sites at PRM (64).  When CI displaces Cro, it 
activates its own expression from the leftwards PRM promoter and represses transcription from 
the PR promoter that transcribes cro and other genes required for lytic growth. This commits the 
phage to exist as a prophage in a lysogen. If Cro remains bound to its operators, then the 
production of lytic genes continues and cI is not produced, committing the bacteriophage to lytic 
growth. 
In lambda, there are two tripartite operator sites to which CI binds with increasing 
affinity during lysogeny (65-68). The repressor has two domains and forms dimers via 
interactions in its C-terminal domain (68). These dimers bind with high affinity to the operator 
OR1 through their N-terminal domains, which contain helix-turn- helix DNA binding motifs (64, 
67, 69-72). Almost immediately, a second repressor dimer complex interacts with the C-terminal 
domains of the bound dimer, allowing it to cooperatively bind to OR2 and form a tetramer (12, 
69). By binding to OR1, the repressor physically blocks RNA polymerase from binding the Cro 
promoter, which prevents transcription of a cascade of early lytic genes. As a result of binding to 
OR2, the repressor physically interacts with domain 4 of the alpha subunit of RNA polymerase 
(73, 74) and stabilizes the enzyme, which promotes binding to the cI promoter with greater 
affinity, activating transcription of more repressor and creating a positive feedback loop (75). 
When repressor concentrations increase enough for a repressor dimer to bind to OR3, 
which is located within PRM, it blocks RNA polymerase transcribing cI and repressor levels 
decrease. Binding to OR3 occurs at a much lower affinity due to lack of cooperative interaction 
with other dimers (76, 77). As repressors levels fall, dimers no longer bind to OR3, allowing 
renewed transcription of cI. This difference in affinity allows the repressor to autoregulate its 
expression during lysogeny and respond to fluctuations in the cellular environment without being 
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hypersensitive. A threshold concentration of repressor must be achieved before the switch can be 
flipped (45). 
Cooperativity also occurs between repressor proteins bound to three operator sites 
approximately 2kb away on the opposite end of the cI gene, OL1, OL2, and OL3 (69, 78-80). The 
repressor binds to these three sites with similar affinities as it does to OR1, OR2, and OR3, 
respectively. Repressor tetramers bound to OR1 and OR2 bind cooperatively through its C-
terminus with tetramers bound at OL1 and OL2 to form an octomer that loops the DNA containing 
the cI gene, increasing its ability to autoregulate its expression by isolating it from the rest of the 
genome (78). When dimers bind OR3 and OL3, they tetramerize and block cI expression until the 
repressor concentration decreases enough for the tetramer to dissociate and transcription to 
resume. 
During lysogen induction, when host DNA is damaged, the SOS response is activated 
and expression of RecA protease is upregulated (12, 64). This protease cleaves multiple host 
repressor proteins and also stimulates self-cleavage of the lambda repressor at the linker region 
between its N-terminal DNA-binding domain and its C-terminal domain (81). When the lambda 
repressor is cleaved, it can no longer bind cooperatively to the operator sites and when enough 
proteins are degraded, transcription of Cro begins, allowing the phage to undergo lytic growth. 
When Cro proteins are expressed, they form dimers and bind with a greater affinity to 
OR3, which creates a physical block against cI transcription (51, 52, 82). Unlike the lambda 
repressors, Cro cannot bind to OR2 cooperatively and it cannot activate RNA polymerase. 
Therefore, when Cro levels rise and dimers bind OR2, cro transcription stops until the Cro 
protein levels fall enough for OR2 to become unoccupied again.  Cro is the first gene in an 
operon of genes needed for prophage excision and DNA replication. 
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1.2.2 Mycobacteriophage L5 
Mycobacteriophage L5 is a temperate phage that uses a single repressor to regulate transcription 
during the establishment and maintenance of lysogeny (3, 83-85).  This repressor, gp71, has two 
domains separated by a short linker region, similar to the lambda repressor.  The N-terminal 
domain contains a strongly predicted helix-turn-helix DNA-binding motif and the repressor 
binds as a monomer to a highly conserved, 13bp asymmetric binding motif on double-stranded 
DNA (not ssDNA or RNA as determined by studies done with the repressor of 
mycobacteriophage L1, which is homoimmune to L5), even though the protein is capable of 
dimerization (86-88).  Gp71 can bind to operator sites within promoter regions to block 
transcription initiation (83), such as within the Pleft promoter responsible for transcribing right-
arm genes that are involved in replication and initiating the lytic lifecycle (89-91), as seen in 
other phage regulatory circuits.   
Interestingly, L5 contains approximately 30 copies of the 13bp binding site across the 
length of its genome and studies have shown that when gp71 binds to sites downstream of the 
promoter, it is capable of blocking transcription elongation (83).  This activity is dependent on 
the sequence of the binding site being oriented in the direction of transcription, and when 
multiple sites are clustered together, the blockage of transcription elongation is cumulative.  (92-
94)   
This “stoperator” method of ensuring immunity is shared among all the Cluster A phages 
(over 200 phages grouped according to sequence similarity (22)). While more work needs to be 
done to understand the L5 genetic switch, including identifying other players involved, how the 
switch is flipped, and how lysogeny is maintained, the identification of this repressor, which is 
capable of exerting an effect on two stages of transcription (initiation and elongation) shows an 
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example of the types of regulatory elements that are waiting to be discovered in 
mycobacteriophages.   
1.2.3 Mycobacteriophage BPs and Integration-Dependent Immunity 
Mycobacteriophage BPs is a temperate phage that has the ability to expand its host range to 
infect M. tuberculosis (95, 96).  It has one of the smallest phage genomes sequenced to date (96).  
This phage is unusual because the core of the phage attachment site (attP), where site-specific 
recombination between the BPs genome and the bacterial chromosome occurs during integration, 
is located within the open reading frame (ORF) of the repressor gene (gene 33) (97).  As a 
consequence, the prophage form of the repressor (gp33103) is truncated by 33 amino acids 
compared to the virally encoded form (gp33136).  
This unusual organization is seen in over 10 mycobacteriophages (six from Cluster G (96, 
98, 99), three from Subcluster I1 (97), two from Cluster N (98), and one from Cluster P (98)) as 
well as the prophages of other species (97).   
1.2.3.1 Genetic Switch 
In mycobacteriophage BPs, upon infection of a host cell, two divergent promoters located within 
the gene 33-34 intergenic region of the genome, PR and Prep, are active, initiating synthesis of 
gene 34, a putative cro-like protein and the first gene of an early lytic operon, as well as gene 33, 
the repressor gene and gene 32, the integrase gene, respectively (Figure 1)(97).  Prep is twice as 
active as PR, indicating that there is a fragile balance in expression between these promoters that 
is important in determining the outcome of infection.  In this genetic switch, the integrase (gp32) 
determines the outcome of infection.  When cellular proteases are low, or when phages infect at a 
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high multiplicity of infection (moi), then gp32 is active, integration occurs, and lysogeny is 
initiated (97).  Since Prep is twice as active as PR, gp32 is initially expressed at a higher rate than 
the early lytic genes, therefore Prep is responsible for lysogenic establishment.   
 
 
Figure 1 - BPs genome map with immunity cassette highlighted 
The mycobacteriophage BPs genome is shown with a ruler representing the length of the genome 
and colored boxes indicating open reading frames.  Boxes above the ruler are transcribed 
rightward, boxes below the ruler are transcribed leftward.  The immunity cassette is zoomed in.  
There are three genes involved in conferring immunity: gene 32 (integrase), gene 33 (repressor), 
and gene 34 (putative cro-like protein).  The attP core is located within the repressor open 
reading frame.  Upon integration the 3’ end of the gene is removed, which leads to the 
expression of a shorter, stable form of the repressor (gp33103). 
 
Integration leads to the initiation of lysogeny because the site at which site-specific 
recombination occurs between the phage genome and host chromosome during genome 
integration (attP core) is located within the repressor open reading frame, such that upon 
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integration the 3’ end is removed from the rest of gene 33 (Figure 1) (96, 97).  This leads to a 
truncated form of the repressor being expressed in the prophage (gp33103).  This shortened 
repressor gene is still attached to the constitutive Prep promoter and is expressed throughout 
lysogeny, therefore Prep is also involved in lysogenic maintenance.  The 33 amino acids that are 
removed from the C-terminus of the protein by this integration process encode an ssrA-like tag 
for proteolytic degradation, possibly by the ClpXP protease (97, 100, 101).  So although the viral 
form of gene 33 (gp33136) is expressed upon infection, it is rapidly degraded and cannot 
accumulate to exert an effect.  Therefore, integration is the process responsible for flipping the 
switch.  Removing the tag and allowing the active form of the repressor to be expressed and 
exert its effect on transcription assures lysogeny.   
Once enough gp32 is made to allow integration, recombination occurs and gene 32 is 
separated from the Prep promoter and expression of integrase ceases (97).  The remaining gp32 is 
degraded, and there is insufficient integrase left to catalyze the excision reaction.  If gp32 is not 
present in sufficient quantities to allow integration (due to low moi or high host protease 
conditions), the full-length repressor continues to be degraded and lytic proteins accumulate to 
block transcription of genes 33 and 32.  It is unknown how gp32 accumulates to catalyze the 
excision reaction during induction of lytic growth from the lysogenic state, since it has no 
requirement for a recombination directionality factor (RDF) and it is separated from its native 
promoter by integration (97).  We theorize that it is expressed either from a cryptic promoter 
within the gene 32-33 intergenic region, which is upstream of gene 32 after integration, or that it 
is expressed from a nearby bacterial host promoter whenever conditions are right for phage 
induction.   
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This is the first instance of integration-dependent immunity described and it provides yet 
another example of the rich diversity of genetic regulatory mechanisms found in 
mycobacteriophages.   
1.2.3.2 Gene 33-34 Intergenic Regulatory Region 
The 33-34 intergenic region contains two divergent promoters, one for rightward expression of 
an early lytic operon (PR) (97, 102) and one for leftward expression of genes 33 and 32, encoding 
repressor and integrase proteins respectively (Prep)(97) (Figure 2).  Both of these promoters have 
been experimentally determined using RNA seq, promoter trap, and fluorescence reporter assays 
(102, 103).  Fluorescence reporter assays with each promoter fused to a mCherry reporter gene 
have also shown that Prep has twice as much activity as PR, and that in a lysogen the PR promoter 
is tightly downregulated, whereas the Prep promoter is not.  In the presence of the active form of 
repressor, Prep is actually modestly upregulated (97, 104).     
 
Figure 2 - The BPs 33-34 intergenic region 
The sequence of the BPs 33-34 intergenic regulatory region is shown.  The -10 and -35 
sequences of the PR and Prep promoters are shown in green text with confirmed transcription start 
sites indicated with a “+1”.  The original locations of OR and ORep are highlighted in yellow.  
Some sequence into the gene 33 (blue) and gene 34 (orange) open reading frames is also 
included.   
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The transcription start sites of these promoters have been mapped (97, 105) and the 
promoters are confirmed to be leaderless (which seems to be common with mycobacterial 
promoters – (105)).  Figure 2 shows the sequence of the 33-34 intergenic region.  The PR and 
Prep promoters are shown along with their transcription start sites and the first few bases of the 
open reading frames of genes 33 and 34.  The divergent nature of these promoters is reminiscent 
of the lambda phage system where PR and PRM are located, and suggests that the BPs repressor 
may exert a function in this area.   
1.3 PROKARYOTIC TRANSCRIPTION 
Bacteriophage transcription works similarly to bacterial transcription because in most cases, the 
infecting phage is utilizing host transcription machinery to express its own genes.  This section 
offers a brief overview of prokaryotic transcription, to create a foundation for examining how 
repressor proteins affect transcription in later chapters.   
1.3.1 Bacterial RNA polymerase 
The crystal structures of many bacterial DNA-dependent RNA polymerases have been resolved, 
however the structure of mycobacterial RNA polymerases have only been modeled from 
structures of Escherichia coli and Thermus aquaticus RNA polymerase (106-110).  These 
structures show that the core enzyme has four subunits, which are evolutionarily conserved in all 
bacterial species (111): two alpha subunits, a beta subunit, and a beta prime subunit.  This core 
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enzyme has the ability to bind and travel along DNA (112), but requires an additional subunit, 
the sigma factor, in order to specifically bind to a promoter sequence and initiate transcription 
(113, 114).   
1.3.2 Sigma factors 
Sigma factors are the transcription initiation factors of RNA polymerase that specifically 
recognize promoter sequences.  While some sigma factors are conserved between species (Sigma 
70 family - (115)) most are unique to different bacterial species (116-118).  Different sigma 
factors are used in different environmental conditions, for example E. coli sigma 32 is expressed 
whenever the bacteria is in a high heat environment and this sigma factor allows expression of 
the E. coli heat shock proteins (119).  Depending on their gene expression needs, some bacteria 
have more or fewer sigma factors than others.  E. coli has seven recognized sigma factors (120) 
whereas M. smegmatis and M. tuberculosis have 28 and 13 respectively. (118, 121-125).   
When sigma subunits bind to an RNA polymerase core enzyme, they allow the 
polymerases to bind with high affinity to particular DNA sequences, called promoters.  Some 
promoters are easy to recognize, such as the sigma 70-family of promoters (126).  These 
promoters have consensus -10 and -35 motifs, which are appropriately named for their locations 
10bp and 35bp upstream of the transcription start sites (127).  The promoters of other sigma 
factors in other species do not always have such readily identifiable sequences in their 
promoters, making their bioinformatic prediction more difficult (128).   
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1.3.3 Initiation, elongation, and termination 
There are three stages of transcription in prokaryotes: initiation, elongation, and termination.  
Although elongation and termination are important determinants of gene expression (129), 
transcription initiation, starting with binding of the RNA polymerase to a specific promoter 
sequence, is generally considered the most influential for gene expression. 
Transcription initiates when an RNA polymerase holoenzyme interacts with a specific 
promoter sequence (130).  The most well understood promoters are the ones recognized by the 
housekeeping sigma 70-like sigma factors (126).   These promoters have a well-characterized -10 
and -35 element separated by a ~17bp spacer region.  The sigma factor recognizes the -35 
element and binds to it.  Then the RNA polymerase is able to switch from its unbound closed 
complex to the open complex where it melts the AT-rich DNA at the -10 site and unwinds ~13bp 
of DNA to create the transcription bubble (131).  At this point the RNA polymerase begins 
incorporating ribonucleotides and synthesizing an 8-9bp RNA strand.  It undergoes a few rounds 
of abortive initiation until the polymerase synthesizes a long enough RNA strand to release its 
interactions with the promoter, and then elongation begins (132).   
Once the RNA polymerase complex escapes the promoter it begins to move along the 
DNA strand creating an mRNA transcript in the 5’ to 3’ direction.  This process is known as 
elongation of the transcript (132).  Many bacterial promoters control gene operons, meaning that 
multiple genes are transcribed in the same transcript, which are then differentially translated by 
ribosomes (133).  RNA polymerase continues elongating the transcript until it encounters a 
terminator.   
When the RNA polymerase elongation complex reaches a terminator, elongation ceases 
and the nascent RNA strand is released.  Prokaryotic terminators come in different forms.  A rho-
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dependent terminator involves the rho protein actively dislodging RNA polymerase (134).  A 
rho-independent, or intrinsic terminator is typically a DNA structure composed of a T-tract that 
pauses the RNA polymerase when it becomes a U-tract on the RNA strand, and a hairpin loop, 
that dislodges the RNA polymerase from the DNA (135, 136).  
1.4 PROTEIN-DNA INTERACTIONS 
The bacteriophage repressor discussed in the following chapters is a DNA-binding protein.  To 
understand the nature of the interactions this protein has with its DNA-binding sites it will be 
helpful to have an understanding of how DNA-binding proteins interact with their substrates.  
This section provides a brief introduction into the structural relationships between DNA binding 
proteins and their substrates with a focus on the specific nature of their interactions.   
1.4.1 What structures define a DNA-binding protein? 
DNA binding proteins contain a large range of different structural motifs that lead to their ability 
to bind DNA.  Some DNA binding proteins, such as lambda cI, use alpha helices to interact with 
the major and minor grooves of DNA (137-142).  These include, but are not limited to, Helix-
turn-helix motifs (143, 144), helix loop helix motifs, and leucine zipper motifs (145-148).  Some 
proteins, for example TATA box binding proteins, use beta sheets to interact with the minor 
groove of DNA (149, 150). And some proteins use a combination of both alpha helices and beta 
sheets, such as those with zinc finger domains (151).   
 
 17 
1.4.2 DNA structure affects protein binding 
DNA is sometimes a double helix and its structure varies slightly depending on its sequence 
(152, 153).  DNA binding proteins use these variations in structure to recognize specific DNA 
sequences (154).  AT-rich and GC-rich sequences typically have a helix structure of B-DNA, 
however the electrostatic potential in the minor grooves of DNA are different (155-159).  A-
tracts (a series of A-T bases) lead to a bend in the DNA due to a slight roll, which leads to 
expanded grooves on one face of the helix and compacted grooves on the other (160-163).  The 
different structural environments formed by these types of sequences provide optimal binding for 
different types of DNA-binding proteins.   
1.4.3 How proteins recognize DNA substrates 
One of the most obvious ways that proteins recognize DNA substrates is through specific 
interactions between residues in their binding domains and the specific chemistries of base pairs 
in the major or minor groove of DNA (137, 164, 165).  These interactions can be very specific 
(formed by hydrogen bonds) or less specific (formed by hydrophobic contacts) (164-167).  
Hydrophobic interactions can also be used by proteins to recognize single-stranded DNA.  
Another way proteins can specifically recognize DNA is by the structure of their major and 
minor grooves (152, 154, 168).  When major and minor grooves become narrower or wider 
based on changes in DNA structure, they become amenable to being bound by different proteins.  
Whether by sequence-specific, or structure-specific interactions, there are a lot of different 
factors that govern specificity of DNA binding proteins to their substrates and most use a 
combination of different recognition factors. 
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2.0  CHARACTERIZING THE DNA-BINDING CAPABILITIES OF GP33103 AND 
GP33136 
Work done in this section was published in the following journal articles: 
Broussard, G.W., Oldfield, L.M., Villanueva, V.M., Lunt, B.L., Shine, E.E., Hatfull, 
G.F., January 2013.  Integration-Dependent Bacteriophage Immunity Provides Insights into the 
Evolution of Genetic Switches.  Molecular Cell, Volume 49, Issue 2, Pages 237-248.  
Villanueva, V.M., Hatfull, G.F., September 2015.  An Unusual Phage Repressor 
Encoded by Mycobacteriophage BPs. PLoS One, Volume 10:e0137187.   
 
2.1 INTRODUCTION 
It has been shown that wild type BPs cannot infect a M. smegmatis BPs lysogen because a BPs 
lysogen confers homoimmunity to superinfection.  M. smegmatis strains have been engineered to 
stably express both gp33103 and gp33136 at similar levels and wild type BPs can lytically infect a 
strain expressing gp33136, but not a strain expressing gp33103, indicating that gp33103 is the active 
form of the repressor (97).  Therefore BPs confers repressor-mediated immunity to 
superinfection.  The first step in characterizing the repressor’s function is to identify its operator 
sites and characterize the repressor’s DNA-binding capabilities.  In this chapter we will discuss 
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the initial experiments done to characterize the gp33103 and gp33136 binding profiles to the 
primary operator within the 33-34 intergenic region and the evidence for other operators across 
the BPs genome. 
2.2 MATERIALS AND METHODS 
2.2.1 Expression and Purification of Mycobacteriophage BPs gp33103 and gp33136 
The gp33103 and gp33136 genes were PCR amplified from a BPs lysate using primers 5’-CAA 
TCG CCC ATA TGT CGC AAG CAT TCG -3’ / 5’- GAC TAC AAG CTT TCA GAA GGT 
TGG GGG TTC GA 3’and 5’-CAA TCG CCC ATA TGT CGC AAG CAT TCG -3’/ 5’- TGC 
CGG AAG AAG CTT TCA CGA CGC TTT ATC C -3’ respectively, which amplified the genes 
with NdeI recognition sites at the 5’ end of the gene and HindIII recognition sites at the 3’ end.  
Each gene was cloned into a maltose-binding fusion vector (pLC3) that was linearized with NdeI 
and HindIII sites for directional cloning, creating two plasmids pVMV20 and pVMV27 for 
gp33103 and gp33136 respectively. pVMV20 and pVMV27 were transformed into BL21(DE3)star 
chemically competent cells (Invitrogen) and grown until cultures reached an OD600 of 0.4-0.6. 
Protein expression was induced with 1 mM IPTG at 17°C overnight. Cells were pelleted and 
frozen at -80°C. Thawed cell pellets were resuspended in 5mL per gram of Lysis Buffer (50 mM 
Tris pH 8.0, 500 mM NaCl, 8% glycerol, 1 mM EDTA and 1 mM β-mercaptoethanol) and lysed 
in 200 mL fractions by sonicating 10 times for 10 sec at 30% output with 30 sec of cooling on 
ice in between bursts. Pooled cell lysates were cleared by centrifugation at 30,000 x g for 40 min 
at 4°C. Fusion proteins were extracted from soluble cell lysates using amylose resin affinity 
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chromatography (Invitrogen) and the MBP tag was cleaved (169) from the proteins of interest 
with TEV protease during overnight dialysis (1,000 MWCO dialysis tubing – Spectra/Por) at 
4°C. MBP and TEV protease contain C-terminal His tags and were removed from the gp33 
proteins using nickel affinity chromatography. The flow through containing pure gp33 proteins 
was dialyzed into a storage buffer (50 mM Tris pH 8.0, 500 mM NaCl, 50% glycerol, 1 mM 
EDTA, 1 mM BME) and stored at -20°C.   
2.2.2 Electrophoretic Mobility Shift Assays 
DNA binding assays were carried out according to standard protocols (170, 171). Briefly, DNA 
substrates (either PCR substrates or annealed complimentary synthetic oligonucleotides; Table 
S1) were 5’ radiolabeled using ATP, [γ-32P] with T4 polynucleotide kinase (Roche). Binding 
reactions contained 5-20 cps radiolabeled DNA probe, 1 µg non-specific calf thymus DNA, and 
varying concentrations of protein in a binding buffer containing 20 mM Tris pH 7.5, 10 mM 
EDTA, 25 mM NaCl, 10 mM spermidine, and 1 mM DTT for a total volume of 10 µl. Reactions 
were incubated at room temperature for 30 min and the resulting protein DNA complexes were 
resolved on a 5% native gel and detected using autoradiography and a phosphorimaging plate. 
Substrates used in this Chapter are listed in Table 1 below.   
2.2.3 Creation and radiolabeling of DNA substrates 
All substrates created by PCR amplification in this chapter were amplified from a wild type BPs 
lysate using high fidelity Cloned PFU DNA polymerase with the primers listed in Table 1.  After 
PCR amplification, the resulting substrates were run on a 0.8% agarose gel, excised, and gel 
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extracted using a GeneJet gel extraction kit from Fermentas.  Substrate concentrations were 
determined via NanoDrop and diluted to a concentration of 10-20ng/µl depending on the initial 
concentration.  25µl of the diluted substrate was 5’-end radiolabeled using ATP, [γ-32P] and T4 
polynucleotide kinase (Roche) according to manufacturer recommendations and the reaction 
volume was brought to 50µl and cleaned up on an illustra ProbeQuant G-50 micro Column (GE 
Healthcare) according to manufacturer recommendations.  The counts per minute (cpm) were 
measured using a Geiger counter and between 5,000-20,000 cpm were used in each EMSA 
reaction.  
Synthetic complimentary single-stranded DNA oligonucleotides were designed and 
ordered from Integrated DNA Technologies with standard desalting specifications.  These 
oligonucleotides were resuspended in pure water to a concentration of 100µM.  0.5µl of one 
strand (typically the forward strand) was 5’-end radiolabeled using ATP, [γ-32P] and T4 
polynucleotide kinase (Roche) according to manufacturer recommendations and the reaction 
volume was brought to 50µl and cleaned up on an illustra ProbeQuant G-50 micro Column (GE 
Healthcare) according to manufacturer recommendations.  To the cleaned up reaction, 5.05µl of 
10x annealing buffer (100mM Tris pH 7.5, 500mM NaCl) was added along with 0.5µl of the 
unradiolabeled (typically the reverse) strand.  This mixture was vortexed briefly and spun down, 
then placed in a 95°C waterbath for 5 minutes.  The waterbath was then turned off and allowed 
to cool to room temperature overnight allowing the complimentary radiolabeled and 
unradiolabeled strands to anneal.  The cpm of the resulting dsDNA oligonucleotides were 
measured using a Geiger Counter and diluted appropriately with pure water so that between 
5,000-20,000 cpm were used in each EMSA reaction. 
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2.2.4 Size Exclusion Chromatography 
Purified gp33103 was dialyzed into a buffer containing 10 mM Tris, pH 8.0, 1 mM BME, 500 
mM NaCl, and 4.5% glycerol using 1,000 MWCO dialysis tubing (Specra/Por). 1.2 mL of 
protein was run over a G-120 column using FPLC, 0.5 ml elution fractions were collected and 
peaks was identified with UV 280 absorbance measurements. Gel filtration molecular weight 
markers (Sigma-Aldrich) were resuspended in the same buffer at manufacturer recommended 
concentrations and run over the same column. The molecular mass for the gel filtration standards 
were plotted against elution volume (Ve) over void volume (Vo) to determine the molecular 
mass of gp33103 based on its elution volume as previously described (169, 172).  
2.2.5 Susbtrates used in this Chapter 2 
 
Table 1 - Substrates used in Chapter 2 DNA Substrate Name Sequence/Primers used 
33-34 intergenic region (226bp) – Fig. 7 Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: GTGTAGTGATCGCTTCGGAATGTCATGC 
33-34 intergenic region (366bp) – Fig. 7 Fwd: CACGGGGTAGCGGCTGTTCGTCG Rev: TGCGGGTTCTGGCTGGTGGGGTC 
5-6 intergenic region – Fig. 7 Fwd: AACGTAGCCACACACGACGCTTGC Rev: ATTCGCCATGCTGCTTGCTCCCGGT 
26-27 intergenic region – Fig. 7 Fwd: TGCCGTGGCGCTGATTCTGAGGTAA Rev: GCATCGGGAAGAAACGATCGGCCAT 
54-55 intergenic region – Fig. 7 Fwd: CACGGGGTAGCGGCTGTTCGTCG Rev: TGCGGGTTCTGGCTGGTGGGGTC 
60-61 intergenic region – Fig. 7 Fwd: GGCGAGTTCGACGCGCCCGT Rev: TGGCCTTGTTGGTGTCGCGTGGAG Mt-3 – Fig. 6 Fwd: TTCGGGCGTGGCGCATTTTCCAATAGA Rev: GTGTAGTGATCGCTTCGGAATGTCATGC 
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OR competition assay oVMV-6: GCATTTTCCAATAGACGACATATGTCGCTATGTTGGTGCACA oVMV-6.2: TGTGCACCAACATAGCGACATATGTCGTCTATTGGAAAATGC OR4 competition assay oVMV-7: GCATTTTCCAATAGACcAgATgTGTtGCTATGTTGGTGCACA oVMV-8: TGTGCACCAACATAGCaACAcATcTgGTCTATTGGAAAATGC ssDNA Top Strand: GCATTTTCCAATAGACGACATATGTCGCTATGTTGGTGCACA Bottom Strand: TGTGCACCAACATAGCGACATATGTCGTCTATTGGAAAATGC 1 12bp OR oVMV-37: agctccgagctcgcg*CGACATATGTCG*gcgagctcgcgagct oVMV-38:  agctcgcgagctcgc*CGACATATGTCG*cgcgagctcggagct ½ 12bp OR oVMV-55: GCTCTCCCAGCACTCCGTCCACCGACG*CGACAT*CAGCCTGGCAAGGTGCCTTGGCAGCGG oVMV-56: CCGCTGCCAAGGCACCTTGCCAGGCTG*ATGTCG*CGTCGGTGGACGGAGTGCTGGGAGAGC 1 12bp OR in native sequence oVMV-79: GGGCGTGGCGCATTTTCCAATAGACGACATATGTCGCTATGTTGGTGCACATGACCCCAA oVMV-80: TTGGGGTCATGTGCACCAACATAGCGACATATGTCGTCTATTGGAAAATGCGCCACGCCC 1 12bp OR in non-native sequence oVMV-39: CTCCCAGCACTCCGTCCACCGACGCGACATATGTCGCAGCCTGGCAAGGTGCCTTGGCAG oVMV-40:  CTGCCAAGGCACCTTGCCAGGCTGCGACATATGTCGCGTCGGTGGACGGAGTGCTGGGAG 
 
Table 2 - Binding affinities of selected substrates in Chapter 2 
Substrate 
Name Average Calculated Kd (Molar) 
Wild type 33-34 
intergenic 
region 2.61 x 10-6 
5-6 intergenic 
region 2.75 x 10
-6 
26-27 intergenic 
region 9.00 x 10
-7 
54-55 intergenic 
region 2.60 x 10
-6 
60-61 intergenic 





2.3.1 Mycobacteriophage BPs repressor binds DNA 
The active mycobacteriophage BPs repressor, gp33103, was purified as described in 2.2.1 and 
used in DNA binding assays as described in 2.2.2.  The substrates tested were prepared 
according to section 2.2.3 and the substrates used are listed in Table 1.   
2.3.1.1 gp33103 and gp33136 binding to the gene 33-34 intergenic region 
Electrophoretic mobility shift assays (EMSA) show that gp33103 binds to DNA substrates 
containing the 33-34 intergenic control region to form several distinct complexes (C1, C2, C3, 
C4) as protein concentration increases (Figure 3A) (97). The combined affinity for gp33103 
binding is relatively weak (2.6 µM) and the prominent complex (C4) forms at protein 
concentrations of 16 µM and above.  Three faster migrating complexes are observed at lower 
protein concentrations and are likely binding intermediates. Although DNA binding is relatively 
weak compared to other repressors, it is specific as little or no binding is observed with a control 




Figure 3 - Binding Profile of gp33103 to the 33-34 intergenic region 
A) EMSA analysis shows that gp33103 binds to the 33-34 intergenic region with a complicated 
pattern of binding with four distinct complexes, labeled C1, C2, C3, and C4. B) No binding was 
seen between gp33103 and a non-speciic DNA substrate. Protein concentrations are as follows: 1) 
none 2) 0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM.  Substrates are shown 
in Table 1 and Table 2.     
BPs gp33136 is longer than gp33103 because of an additional 33 residues at its C-terminus. 
The C-terminal extension includes the ssrA tag that targets the protein for proteolysis, and 
stabilization of the protein by an A135E substitution gives higher levels of lysogeny. However, it 
was noted that the gp33136 A135E mutant, which acts as an active repressor due to inactivation of 
the ssrA-like tag, appears to give a modest increase in activity of the Prep promoter in a reporter 
fusion assay (97), perhaps providing transcriptional activation that is dependent on the C-
terminal 33 residues. We therefore compared the binding profiles of gp33103 and gp33136 for any 
differences in binding to the 33-34 intergenic region that contains both Prep and PR (Figure 4). 
Both proteins give similar profiles and the additional 33 C-terminal residues in gp33136 do not 
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appear to substantially influence DNA binding. It is likely that any functional activation of Prep 
results from protein-protein interactions, perhaps reflecting direct contacts between BPs gp33136 
and RNA Polymerase.  
 
 
Figure 4 - Comparison of the binding profiles of gp33103 and gp33136 to the 33-34 intergenic region 
DNA binding assays show that both (A) gp33103 and (B) gp33136 bind similarly to a DNA 
substrate containing PCR amplified DNA from the BPs gene 33-34 intergenic region (Table 1).  
Protein concentrations are as follows: 1) none 2) 0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 
16 μM, 7) 54 μM.   
The 185 bp DNA segment contains only a single copy of the 12 bp sequence 5’-
CGACATATGTCG that was previously predicted to be recognized by gp33103, but the 
complexes formed are more varied than would be expected for a single protein-DNA interaction. 
Presumably, the protein binds to additional sites within this region, binds with varying protein-
DNA stoichiometries, or imposes significant DNA distortions. It is important to note that there is 
a related sequence (5’-CGACATACCGGC) at the left end (33-proximal) of the intergenic region 
that overlaps the Prep transcription start site (Figure 2), although the similarity is restricted to the 
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left-most seven base pairs of the sequence motif. We therefore sought to dissect the various 
determinants of gp33103 binding to this region, and to compare this to the binding of gp33103 to 
the other sites located elsewhere in the BPs genome.  Most assays were done with gp33103 
because it is more stable than gp33136.   
2.3.1.2 Binding in the rest of the BPs genome 
Both versions of the repressor are capable of binding DNA within the gene 33-34 intergenic 
region, where the bioinformatically predicted operator site (OR) is located (Figure 3).  OR is 
composed of a 12bp palindrome located between the -10 and -35 regions of the PR promoter. 
Since we predicted that OR is the probable repressor binding site within the 33-34 intergenic 
region, we searched the rest of the BPs genome for similar sequences.  Three other areas were 
found that contain sites identical to the 12bp OR operator within the 5-6, 26-27 and 54-55 
intergenic regions.  The intergenic regions containing these other potential operators were PCR 
amplified from a wild type BPs lysate and used as substrates to test for gp33103 binding in EMSA 
assays.  They all showed binding, although each binding profile is different and the protein binds 





Figure 5 - Binding Profile of gp33103 to other areas of the BPs genome 
The BPs genome contains three occurrences of the 12bp palindrome 5’ – CGACATATGTCG 
outside of the 33-34 intergenic region.  EMSAs were performed on substrates containing the 
intergenic regions where these sequences are located to show that gp33103 binds to all of them, 
albeit with simpler binding profiles.  Substrates are shown in Table 1 and Table 2.  Protein 
concentrations are as follows: 1) none 2) 0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 
7) 54 μM. 
 
These findings suggest that the predicted 12bp palindromic operator is a true binding site, 
and that the repressor could exert an effect in multiple areas of the phage genome.  The 5-6 and 
54-55 intergenic regions have been found to contain promoter activity, so presumably the 
repressor could be shutting down multiple operons during lysogeny (97, 102).  The 26-27 
intergenic region does not contain strong promoter activity (103), however it lies upstream of 
two late-lytic lysin genes, so gp33103 could perhaps play a role in blocking any leaky expression 
that could lead to expression of these lytic genes (103).  
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2.3.2 Confirmation of the gp33 operator.   
2.3.2.1 Unradiolabeled operator DNA competes out gp33103 binding 
To prove that the repressor binds to the 12bp OR, we performed a competition assay by adding 
specific un-radiolabeled probes containing the 12bp OR sequence to a reaction where gp33103 
was interacting with a radiolabeled probe derived from the right half of the 33-34 intergenic 
region (amplified from Mt3 primers; Table 1).  42 bp complimentary single-stranded DNA 
oligonucleotides were engineered to contain the 12bp OR operator site plus 15 base pairs on each 
side of surrounding native sequence with either wild type 12bp OR sequence (denoted as OR) or 
with the 12bp OR containing four point mutations (denoted as OR4) as shown in Table 1.  These 
single-stranded oligonucleotides were annealed as described in section 2.2.3 but without 
radiolabeling.  Binding reactions were set up containing 16µM gp33103 and ~15ng of 
radiolabeled Mt3 DNA (containing OR and some surrounding sequence - conditions shown to 
cause a single shift on a gel  - Table 1, Figure 6).  Increasing concentrations of unradiolabeled 




Figure 6 - Competition assay with unradiolabeled OR DNA 
A DNA substrate containing the operator site (Mt3 – Table 3 and Table 4) was radiolabeled and 
incubated with gp33103 at a concentration of 16µM.  Increasing concentrations of unradiolabeled 
probe containing the operator site (wild type, OR, and with four point mutations, OR4) and 15bp 
of native sequence on either side were added and the binding was outcompeted.  Concentrations 
of unradiolabeled probe in lanes are as follows: 1) 10µM, 2) 30µM, 3) 50µM, 4) 100µM, 5) 
300µM, 6) 500µM.     
Our results show that the presence of cold OR outcompetes the radiolabeled probe for 
gp33103 binding, whereas OR4 does not (Figure 6).  These results suggest that the 12bp OR is an 
operator site and that its sequence is important for binding specificity, but binding assays done 
with the full 33-34 intergenic region, which show four complexes being formed, indicates that 
the left side of the 33-34 intergenic region (not containing OR) might also be important for 
binding.   
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2.3.2.2 Two single point mutations in the 12bp OR lead to repressor insensitive phage 
phenotypes 
Repressor-insensitive mutants are temperate phages that have accumulated mutations allowing 
them to be able to grow lytically on a lawn of host bacteria expressing its active repressor 
protein.  Despite having copious amounts of repressor present, the proteins have no effect on the 
infecting phage genome and the lytic pathway dominates the lifecycle.  Multiple repressor-
insensitive mutants have been isolated from BPs.  The sequences of these phages revealed that 
two of them had single point mutations mapping to the 33-34 intergenic region.  Upon closer 
examination, we noted that these point mutations were both located within the 12bp OR sequence 
(Table 3 and Table 4).   
We amplified the entire 33-34 intergenic region from the two repressor insensitive 
mutants containing single point mutations and performed binding assays on them.  Compared to 
gp33103 binding to a wild type BPs 33-34 intergenic region, the two point mutants only had a 3- 
to 4-fold decrease in binding affinity (Figure 7A).  However when we amplified the right-most 
regions of the 33-34 intergenic region from each phage (using the same Mt3 primers as were 
used in the competition assay in section 2.3.2.1) and did an EMSA with gp33103 on them, they 




Figure 7 - gp33103 binding to two repressor-insensitive mutants 
BPs gp33103 binding to the 33-34 intergenic region (left 3 panels – Table 1) and the right-most 
portion of the 33-34 intergenic region (using Mt3 primers, Table 3) derived from two repressor-
insensitive BPs mutants with single base pair substitutions, 102a (Mut-1) and 102e (Mut-2).  
Binding profiles of gp33103 to each mutated substrate show a decrease in binding affinity 
compared to wild type. The concentrations of protein are as follows: 1) none, 2) 0.16μM, 3) 
0.54μM, 4) 1.6μM, 5) 5.4μM, 6) 16μM, 7) 54µM.  
 
This evidence indicated that not only is the sequence of the palindrome important for the 
repressor’s biological function, but that it is so important that a single point mutation, which 
decreases the repressor’s binding affinity only modestly, is able to prevent host immunity from 
superinfection.  Despite these promising results, the requirements for DNA binding at OR and at 
related sequences elsewhere in the phage genome and the nature of the protein-DNA interactions 
are not well understood.   
2.3.3 Multimeric state of the Mycobacteriophage BPs repressor in solution 
We estimated the oligomeric state of gp33103 in solution. A single protein peak was 
observed using size-exclusion chromatography (Figure 8), and when compared with protein 
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markers of globular shape and low molecular weights, gp33103 has an apparent molecular mass 
of 40.4 kDa (Figure 9). The monomeric mass of gp33103 is 11.2 kDa, and the simple 
interpretation is that the major peak corresponds to a gp33103 tetramer, although we cannot rule 
out the possibility that it is an alternative multimer shaped to give altered elution in the 
chromatography. The 12 bp operator described in the previous sections has dyad symmetry 
consistent with recognition by either a dimer or tetramer of gp33103. The gp33103 elution profile 
did not show any other prevalent forms and the oligomeric state is quite homogenous (Figure 8).  
 
Figure 8 - Size-exclusion chromatogram 
Size-exclusion chromatograms for gp33103 (orange) and the molecular weight markers (green; 





Figure 9 - gp33103 exists as a tetramer in solution The graph shows a standard plot for the molecular mass for the protein standards against the ratio of their elution volume (Ve) and void volume (Vo) (blue diamonds); the molecular mass of gp33103 is predicted to be 40.4kDa (orange diamond). Gp33103 is an 11.2 kDa protein, so it is likely a tetramer in solution.   
2.3.4 Gp33103 binds to other DNA substrates 
2.3.4.1 Gp33103 binds to ssDNA 
To determine that the operator site for gp33103 is a double-stranded DNA binding site, we tested 
whether gp33103 was able to bind single-stranded DNA as well as double-stranded DNA.  In this 
assay, we radiolabeled two complimentary strands of synthetic oligonucleotides engineered to 
contain a central 12bp operator site flanked by 15bp of native sequence on each side.  We tested 
gp33103’s ability to bind to each single-stranded DNA oligonucleotide separately, and then 
annealed them to create a double-stranded DNA substrate of identical sequence for reference and 




Figure 10 - gp33103 binds faintly to single-stranded DNA 
EMSAS were done on a 42bp double stranded DNA substrate containing OR and 15bp of native 
sequence on either side (Table 1).  Each strand of the double-stranded DNA substrate was 
radiolabeled separately prior to annealing.  EMSAs done on these substrates show that gp33103 
binds very weakly to single-stranded DNA.  The left panel is the double stranded DNA substrate, 
the center panel is top strand ssDNA, and the right panel is bottom strand ssDNA.  Protein 
concentrations were as follows:  1) none, 2) 0.16μM, 3) 0.54μM, 4) 1.6μM, 5) 5.4μM, 6) 16μM, 
7) 54µM.   
 
The results show that gp33103 is able to bind each single-stranded DNA substrate only 
very modestly, but it binds strongly to the double-stranded DNA substrate with identical 
sequence (Figure 10).  Interestingly, the mobility of the complexes formed with each of the 
single-stranded DNA substrates runs similarly to the faint fast-migrating complex seen in the 
double-stranded DNA complex.  It is plausible that the faint, faster-moving complexes formed 
when gp33103 binds to synthetically created, annealed oligos could be due to the protein binding 
to un-annealed single-stranded DNA contaminants in the substrate preparation.   Not many phage 
repressors have been shown to bind to single-stranded DNA (88) and the probability of the BPs 
repressor to bind single-stranded DNA and, if it does bind, that it performs a specific biological 
function via that interaction in vivo is unknown.    
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2.3.4.2 Gp33103 binds to operator half-sites 
The leftmost portion of the 33-34 intergenic region, just inside the gene 33 open reading frame, 
contains a 6bp operator half-site.  The 33-34 intergenic region substrates in this chapter all 
contain this half-site due to the location of the primers used to amplify the region (Table 1).  One 
of the potential reasons for multiple complexes being formed when EMSAs are performed on 
these substrates is that gp33103 is able to bind the OR half-site, leading to different protein-DNA 
stoichiometries in each reaction.  To test if gp33103 is able to bind this half-site, we engineered 
synthetic oligonucleotides where we placed the 6bp sequence in a non-native sequence context 
and compared the binding profile of the protein to this substrate to that of a substrate containing 
a full 12bp OR site in a non-native sequence context (Table 1; Figure 11).   
 
Figure 11 - gp33103 does not bind to a 6bp OR half site 
Gp33103 is able to bind to a 60 bp substrate containing the 12 bp OR centrally but not to a 60 bp 
substrate containing a 6 bp OR half site located centrally (Table 1).     
The results indicate that while gp33103 can bind to a full 12bp operator site out of native 
sequence context, it cannot bind to a 6bp half-site (Figure 11).  However, these results do not 
necessarily rule out involvement of the half-site in formation of one or more of the complexes 
 37 
seen when gp33103 binds to the entire 33-34 intergenic region.  In fact, gp33103 may only bind to 
the 6bp half-site cooperatively, and there could be a requirement for a full 12bp site nearby for 
the half-site to be occupied.  This theory suggests that perhaps cooperative binding and DNA 
bending or looping may play a role in formation of the complexes seen when gp33103 binds to the 
33-34 intergenic region.   
2.3.4.3 Native sequence surrounding OR is important for major complex formation 
In its natural sequence, gp33103 binds OR and forms two complexes: a slower-migrating major 
complex, and a faster-migrating complex (Figure 12).  If gp33103 is in fact a tetramer in solution, 
the major band could be a tetramer bound at the OR site and the minor complex could be either a 
dimer or monomer binding to the OR site.  When OR is placed outside of its native sequence 
context, two complexes are again formed, but interestingly, the major complex shifts from being 






Figure 12 - gp33103 binding to OR in a native and non-native sequence context 
EMSAs were done with gp33103 binding to two 60 bp substrates containing a single 12 bp OR site 
located centrally.  One substrate contained 24 bp of native sequence surrounding OR, the other 
contained non-native sequence (Table 1).  Gp33103 has a slower migrating major complex when 
OR is in its native sequence compared to when it is in a non-native sequence.     
In section 2.3.4.2 we suggest a role for DNA bending within the 33-34 intergenic region, 
and such a theory could explain the changes seen in major complex formation between the 
substrates shown in Figure 12.  When OR is centered on a 60bp substrate that is not its natural 
sequence, gp33103 binds to OR and causes a shift (faster-moving complex), but the lack of an AT-
righ region surrounding the operator may not allow the protein to bend DNA very efficiently, 
leading to weaker formation of the slower-moving complex.   However in its native sequence, 
gp33103 could not only bind DNA, but also efficiently bend DNA, which would lead to high 
incidence of a slower-moving complex corresponding to gp33103 bending the DNA substrate it is 
attached to, and also possibly a faster-moving complex where gp33103 binds, but does not bend 




In this chapter we have shown that gp33103 binds with a complicated pattern of binding, but that 
it binds specifically, and that it binds similarly to the gp33136 long form of the protein.  We have 
also identified a 12bp operator site that is present within four intergenic regions across the BPs 
genome.  The primary regulatory region, the 33-34 intergenic region, where two divergent 
promoters exist is where we first identified this binding site and we called it OR.  gp33103 also 
binds within the other three intergenic regions where identical OR-like sites are located.  To 
confirm this as an operator, we performed a competition assay in which an unradiolabeled probe 
competed out the gp33103 binding, and we also examined some repressor-insensitive mutation 
data that showed that a single base pair change in this operator sequence led to dramatic 
consequences in vivo.  Gel filtration chromatography reveals that this protein seems to exist as a 
tetramer in solution, which could help explain some of the many complexes seen when gp33103 
binds to the 33-34 intergenic region.   
We also showed that gp33103 is able to bind to single-stranded DNA weakly.  The 
significance of this experiment in understanding the integration-dependent genetic switch as a 
whole is not great, however it has been shown that proteins that bind to single stranded DNA 
often make hydrophobic interactions with DNA (173).  Bacteriophages P22 and 434 encode a 
cro and repressor protein, respectively, that recognizes DNA via hydrophobic interactions (166, 
167). So perhaps it is not far-fetched to suggest that this is how gp33103 recognizes its operator 
sequence.  Also, there seems to be some dependence on the surrounding sequence of the operator 
for proper binding.  This will be explored in subsequent chapters.   
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3.0  MAPPING THE SEQUENCE REQUIREMENTS FOR GP33103 BINDING 
Work done in this section was published in the following publications: 
Broussard, G.W., Oldfield, L.M., Villanueva, V.M., Lunt, B.L., Shine, E.E., Hatfull, 
G.F., January 2013.  Integration-Dependent Bacteriophage Immunity Provides Insights into the 
Evolution of Genetic Switches.  Molecular Cell, Volume 49, Issue 2, Pages 237-248.  
Villanueva, V.M., Hatfull, G.F., September 2015.  An Unusual Phage Repressor 
Encoded by Mycobacteriophage BPs. PLoS One, Volume 10:e0137187.   
3.1 INTRODUCTION 
We have established that gp33103 is the active form of the BPs repressor and that it is capable of 
binding DNA at a putative 12bp palindromic operator, OR, as well as to three identical sites 
across the BPs genome.  When gp33103 binds to the other identical 12bp sites, a much simpler 
binding pattern is seen than when gp33103 binds within the 33-34 intergenic region.  We sought 
to explain the nature of the complexes seen when gp33103 binds to the gene 33-34 intergenic 
regulatory region and explain why these are formed in this particular area, but not in other 
regions of the genome.  In this chapter we will discuss experiments done to elucidate the nature 
of the C1, C2, C3, and C4 complexes formed when gp33103 binds the 33-34 intergenic region, as 
well as work done to elucidate the true sequence of the operator site, which is two 12bp half sites 
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separated by a spacer region, and the sequence requirements for gp33103 binding and relate that 
to its function in vivo.   
3.2 MATERIALS AND METHODS 
3.2.1 DNase I Footprinting 
Footprinting assays were carried out as previously described (170, 174, 175). Briefly, binding 
reactions were carried out in a final volume of 50 µl containing various concentrations of 
protein, 20cps radio labeled probe, 25 mM Tris-HCL pH 8.0, 50 mM KCl, 6.25 mM MgCl2, 0.5 
mM EDTA, 10% Glycerol, 0.5 mM DTT. Binding reactions were incubated at room 
temperatures for 30min. After incubation, 50 µl of a solution containing 5 mM CaCl2 and 10 mM 
MgCl2 was added to the samples and incubated for 1 minute.  Samples were treated with 1.5U 
DNaseI (Sigma) for exactly one minute, then the digestion reaction was stopped by addition of 
90µl of a pre-warmed (37°C) Stop solution (200 mM NaCl, 30 mM EDTA, 1% SDS, 100 µg/mL 
yeast RNA). Samples were PCI (Invitrogen) extracted and ethanol precipitated. Samples were 
resuspended in 2-3 µl formamide loading buffer and heated to 95°C for 2 minutes before loading 
onto a 6% polyacrylamide 7M urea denaturing gel for resolution. Bands were detected using 
autoradiography or exposed on a phosphorimageing plate and detected on a FLA-5100; FujiFilm 
imaging system.  Sequencing ladders were made as previously described (175, 176).   
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3.2.2 DNA-Binding Assays 
EMSAs were done according to protocol described in 2.2.2.  Substrates used in this chapter were 
prepared as described in 2.2.3 are listed in Table 2 below.   
 
Table 3 - Substrates used in Chapter 3 
DNA Substrate 
Name 
Sequence/Primers used DNase I Footprinting substrate – Fig. 13 Fwd: TCTAGAACCGGCGATTGTATGTAC Rev: AAGCTTGTGCACCAACATAGCGAC Region 1 – Fig. 15 AACCGTGCATATCGCGCAATACACTTGCGACATACCGGCAACGTTGAAACAATCACGTTG Region 2 – Fig. 15 AACCGTGCATATCGCGCAATACAAACATTGTATGGTTGAAACAATCACGTTGCACGTTGC Region 3 – Fig. 15 AACCGTGCATATCGCGCAATACAAACTTCGGGCGTTGAAACAATCACGTTGCACGTTGCA Region 4 – Fig. 15 AACCGTGCATATCGCGCAATACAAACGGCGCATGTTGAAACAATCACGTTGCACGTTGCA Region 5 – Fig. 15 AACCGTGCATATCGCGCAATAAATAGACGACATATGTCGCAAACGTTGAAACAATCACGT TIR-1 – Fig. 18 ACCGGCGATTGTATGTACGTCTGTCGCGTACGCGCAATAT TIR-2 – Fig. 18 CGCGCAATATCGCCGTTCGTCAACCGTTGCGAGCGGAAAC TIR-3 – Fig. 18 GAGCGGAAACGGCACGGCGCGTTGATCCTGGCAAACCGTC TIR-4 – Fig. 18 GCAAACCGTCGGTGGTAACGGATTGCGTGGCAAACGCAAA TIR-5 – Fig. 18 CAAACGCAAAAGTTCGGGCGTGGCGCATTTTCCAATAGAC TIR-6 – Fig. 18 TCCAATAGACGACATATGTCGCT TIR-5.1 – Fig. 19 CAAACGCAAAAGTTCGGGCG TIR-5.2 – Fig. 19 TGGCGCATTTTCCAATAGAC TIR-5.3 – Fig. 19 GATTGCGTGGCAAACGCAAA TIR-5.4 – Fig. 19 AGTTCGGGCGTGGCGCATTT TIR-5.5 – Fig. 19 TCCAATAGACGACATATGTCGCT TIR-5.6 – Fig. 19 GCAAAAGTTCGGGCGTGGCG TIR-5.7 – Fig. 19 GGGCGTGGCGCATTTTCCAA Mt-2 – Fig. 21 Fwd: TTGGTGCACATGACCCCAACCGAAAC Rev: GTGTAGTGATCGCTTCGGAATGTCATGC Mt-3 – Fig. 21 Fwd: TTCGGGCGTGGCGCATTTTCCAATAGA Rev: GTGTAGTGATCGCTTCGGAATGTCATGC Mt-4 – Fig. 21 Fwd: TGGCAAACCGTCGGTGGTAACGGAT Rev: GTGTAGTGATCGCTTCGGAATGTCATGC Mt-5 – Fig. 21 Fwd: GTTCGTCAACCGTTGCGAGCGGAAA Rev: GTGTAGTGATCGCTTCGGAATGTCATGC Mt-6 – Fig. 21 Fwd: ACATACCGGCGATTGTATGTACGTCTGTC Rev: GTGTAGTGATCGCTTCGGAATGTCATGC Mt-7 – Fig. 21 Fwd: ACGAAAGCCTGCTCGGCGGGATC Rev: GTGTAGTGATCGCTTCGGAATGTCATGC Mt-8 – Fig. 21 Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: GTTTCGGTTGGGGTCATGTGCACCAA Mt-9 – Fig. 21 Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: TCTATTGGAAAATGCGCCACGCCCGAA 
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Mt-10 – Fig. 21 Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: ATCCGTTACCACCGACGGTTTGCCA Mt-11 – Fig. 21 Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: tttccGCTCGCAACGGTTGACGAAC Mt-12 – Fig. 21 Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: GACAGACGTACATACAATCGCCGGTATGT Mt-13 – Fig. 21 Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: GATCCCGCCGAGCAGGCTTTCGT O6--L – Fig. 26 CACACACGACGCTTGCACCGCGACATATGTCGGTTTTGCAGACGTGCAGGTT O6-R – Fig. 26 GCATTTTCCAATAGAGGACATATGCGGCTATGTTGGTGCACA O27-R – Fig. 27 GCATCACGGACGCTGCTATCCGACATATGTCGTGGATGATCGGGATATGGCC O27-L – Fig. 27 GCATTTTCCAATAGACCGCATATGTCGCTATGTTGGTGCACA OR-R – Fig. 25 GCATTTTCCAATAGACGACATATGTCGCTATGTTGGTGCACA ORep-R – Fig. 25 TTCGGGCGTGGCGCATTTTCCAATAGACGACATCTATGTTGGTGCACATGACCCCAACCG O55-L – Fig. 28 TCGGACATGGTGAACGCTTGCGACATATGTCGCCAATGTGTGCATCTTTGCA O55-R – Fig. 28 GCATTTTCCAATAGATGACACTTGTCGCTATGTTGGTGCACA O61-R – Fig. 29 GCATTTTCCAATAGACGACATATGTGCCTATGTTGGTGCACA O61-L – Fig. 29 GCATTTTCCAATAGACGACATTCGCGCCTATGTTGGTGCACA 
5-6 intergenic region – Fig. 26 Fwd: AACGTAGCCACACACGACGCTTGC Rev: ATTCGCCATGCTGCTTGCTCCCGGT 
26-27 intergenic region – Fig. 27 Fwd: TGCCGTGGCGCTGATTCTGAGGTAA Rev: GCATCGGGAAGAAACGATCGGCCAT 
33-34 intergenic region (366bp) – Fig. 25 Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: GTGTAGTGATCGCTTCGGAATGTCATGC 
54-55 intergenic region – Fig. 28 Fwd: CACGGGGTAGCGGCTGTTCGTCG Rev: TGCGGGTTCTGGCTGGTGGGGTC 
60-61 intergenic region – Fig. 29 Fwd: GGCGAGTTCGACGCGCCCGT Rev: TGGCCTTGTTGGTGTCGCGTGGAG Repressor-insensitive BPs mutants - 
33-34 intergenic region – Fig. 31 








Table 4 - Binding affinities of gp33103 to selected substrates in Chapter 3 
Mutant Name Specific Mutation within 33-34 intergenic region 
Average Calculated Kd 
(Molar) Wild type 33-
34 intergenic region None 2.61 x 10-6 102a T29489C 7.05 x 10-6 102e A29486C 7.80 x 10-6 102j 151bp Inversion (29282-29432) 4.23 x 10-6 102k 24bp Duplication (29472-29495) 6.67 x 10-6 127b 151bp Deletion (29323-29473) 9.50 x 10-6 127c 33bp Duplication (29495-29527) 3.50 x 10-6 127d 12bp Duplication (29474-29485) 2.99 x 10-6 127e 6bp Duplication (29483-29488) 3.81 x 10-6 
Δ32 Clr1 T29336C 1.74 x 10-6 
Δ32 Clr4 G29500A 1.45 x 10-6 33A129E Clr5 C29372T 2.90 x 10-6 33A129E Clr6 T29475C 2.65 x 10-6 
Δ32 Clr8 T29501C 2.80 x 10-6 
5-6 intergenic region None 2.75 x 10-6 
26-27 intergenic region None 9.00 x 10-7 
54-55 intergenic region None 2.60 x 10-6 




3.3.1 DNase I Footprinting 
Both the viral and prophage forms of gp33103 have been purified.  Previous studies have shown 
that the prophage form of gp33103 binds within the gene 33-34 intergenic region, which contains 
two divergent promoters: one for rightwards expression of an early lytic operon, PR, and one for 
leftward expression of gp33103 and Int (102).  Studies done by Broussard et al. showed that 
gp33103 binds specifically to a 12 base pair palindrome, OR. DNA binding assays from that study 
showed that the binding affinity of the BPs gp33103 to its operator sites is low, with a dissociation 
constant of approximately 1 µM, which is 10-fold higher than that expected for a phage repressor 
(97).  To confirm that gp33103 binds to OR, we performed DNase I footprinting assays (Figure 
13).   
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Figure 13 - DNase I footprinting assay of gp33103 binding to the 33-34 intergenic region 
DNase I footprinting assays (panels A and B) were done using 5’ end-labeled probes of the 33-
34 intergenic region, which were incubated with increasing concentrations of gp33103, subjected 
to DNase I cleavage, and run on a denaturing gel alongside a sequencing ladder. Black arrows 
show the direction of the sequence from 5’ to 3’ for each DNA strand. Regions of protection 
from DNase I cleavage are indicated by black bars and labeled.  Two regions of protection 
observed near Prep, one of which contains ORep (Regions 1 and 2). Three regions of protection are 
observed near PR (Regions 3 and 4, Region 5), one of which includes OR (Region 5).  The 
sequence of OR is shown (OR-R) as well as a predicted second binding site (OR-L) (section 
3.3.2.3). Protein concentrations are as follows: 1) none 2) 0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 
μM, 6) 16 μM, 7) 54 μM, 8) 160 μM.    
Figure 13 shows representative DNase I Foot printing assays – one for each strand of the 
probe. It is evident upon first glance that there seem to be two patterns of altered DNase I 
protection: one when intermediate protein concentrations are added and one when the most 
concentrated protein is used.  When the forward strand of the 33-34 intergenic region was 
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probed, we found two areas of protection from DNase I cleavage separated by an area of 
enhanced cleavage (Figure 13A).  The first area of protection, Region 1, is 16bp long and is 
located just inside of the gene 33 open reading frame.  Upon further examination, we found that 
this area contains an OR half-site that was originally dismissed as a potential binding site due to 
the lack of binding seen when it was isolated in a non-native sequence; however there was no 
evidence to show that the site was unoccupied when gp33103 binds in the presence of the rest of 
the 33-34 intergenic region.  The second area, Region 2, is an 8bp site that could be a 
continuation of Region 1.  The binding of gp33103 to these sites could be dependent upon both of 
them being present on the same substrate, though this second region of protection contains no 
obvious sequence similarity to the 12bp OR.  One curious aspect of this binding profile is that 
there are two areas of DNase I cleavage enhancement surrounding Region 2.  This enhancement 
could mean multiple things, including increased cleavage due to favorable protein-protein 
interactions between gp33103 and DNase I, or perhaps gp33103 caused a change of DNA 
secondary structure, such as DNA bending, leading to greater exposure of those base pairs to the 
enzyme.  From this assay we cannot confirm the cause of the enhancements.   
When the antiparallel (reverse) strand of DNA was probed, we found three areas of 
protection from DNase I cleavage (Figure 13B).  Region 3 and Region 4 are short binding sites 
upstream of OR with no remarkable sequence identity to the 12bp operator site, although it has 
been noted previously (section 2.3.4.3) that the AT-rich nature of the sequence surrounding the 
12bp OR site could have a function in allowing gp33103 to bend DNA. Surrounding Site 3 we 
again see areas of enhanced DNase I cleavage, but we cannot conclude a reason for the 
enhancements from this assay alone.  Region 5 contains the entire 12bp OR site.  Overall we can 
see an area of clearing spanning at least 19 base pairs (Figure 13B).  The sequence gets cut off at 
 48 
the right edge of OR at the bottom of the gel so it is unclear whether there is a larger area of 
protection in that direction.  
 
 
Figure 14 - Regions of protection from DNase I footprinting 
The sequences of the areas of protection from DNase I cleavage are shown in the context of the 
entire 33-34 intergenic region.  
 
The assays showed that gp33103 does indeed bind to the 12bp operator OR, and also to 
four other sites across the region (Figure 14).  To confirm these as true binding sites, we 
performed an EMSA on each site separately in a non-native sequence context (Figure 15) as 
well as each set of sites together based on the area of the 33-34 intergenic region in which they 





Figure 15 - gp33103 binding to Regions of DNase I protection 
DNA binding assays with gp33103 using synthetic oligonucleotide substrates that contain the 
sequence of each region identified in Figure 13, each in a non-native 60 bp sequence context.  
BPs gp33103 only binds to Region 5, which contains OR. Protein concentrations are as follows: 1) 
none 2) 0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM. 
 
When the five sites were isolated from each other in a non-native sequence context, only 
the site containing the full OR showed binding (Figure 15).  But grouped together, Sites 1 & 2 
showed modest binding and Sites 3, 4, and 5 show a more complex binding pattern (multiple 




Figure 16 - gp33103 binding to grouped regions of DNase I protection 
Regions of protection from DNase I cleavage were grouped on a 60 bp DNA substrate according 
to which side of the genome they were on (33-proximal or 34-proximal).  Substrates have non-
native sequence surrounding the Regions, but native sequence between them.  Gp33103 is able to 
bind to Regions 1 and 2, as well as 3, 4, and 5.   Protein concentrations are as follows: 1) none 2) 
0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM.    
These results, along with previous genetic and biochemical data collected (97), show that 
the BPs gp33103 binds specifically to the 12bp OR site as well as the region immediately upstream 
of OR.  These assays also show that gp33103 binds to the opposite end of the 33-34 intergenic 
region where an operator half-site exists, which could be the reason we see such a complicated 
binding pattern in mobility shift assays on this substrate.  The regions of protection at Prep will be 
referred to as ORep from here on out.  It is likely that the slowest moving of the protein-DNA 
complexes seen when gp33103 binds to the 33-34 intergenic region (C4) corresponds to the more 
extensive DNase I protections seen at the highest protein concentration, and that the faster 
migrating complexes correspond to those seen at intermediate concentrations.    
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3.3.2 TIR and End-Deletion Series of Substrates 
3.3.2.1 TIR series of substrates 
We created a series of synthetic double-stranded DNA oligonucleotide substrates spanning the 
33-34 intergenic region and overlapping with each other by only 10bp so as to further explore 
where gp33103 may be binding (Figure 17A).  The results from performing EMSAs on these 
substrates did not show binding in any of the substrates except TIR-5 and TIR-6 (Figure 18).  
We did not see any binding to the TIR-1 substrate containing Region 2 from the DNase I 
footprinting results (section 3.3.1), which is not surprising since we already showed in Figure 15 
that gp33103 did not bind to Region 1 or Region 2 when isolated from each other.   
 
 
Figure 17 - TIR series of substrates in the context of the full 33-34 intergenic region 
(A) The sequences and relative positions of the TIR series of substrates within the 33-34 
intergenic region are shown.  (B) The sequences of the derivatives of the TIR-5 substrate are 




Figure 18 - gp33103 binding to the TIR series substrates 
EMSAs showing gp33103 binding to 40 bp substrates spanning the 33-34 intergenic region (see 
Figure 17). Binding occurs to the TIR-6 fragment containing the 12bp OR (OR-R) and to substrate 
TIR-5, which contains Region 3 and Region 4 (OR-L) and only one base pair of OR-R.  Protein 
concentrations are as follows: 1) none 2) 0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 
7) 54 μM.  See Table 3 for substrate sequences and Table 4 for binding affinities.    
 
Interestingly, the area we do see binding to (apart from TIR-6, which contains the 12bp 
OR) is the TIR-5 substrate that is adjacent to, but does not include, the 12bp OR (Figure 18).  
This substrate contains one base pair from the OR site and 39 base pairs of sequence to the left of 
OR, including Region 3 and Region 4 from DNase I footprinting.  The binding seen is not very 
strong, however it is present.  To narrow down where within this TIR-5 substrate gp33103 was 
binding to, we created seven new double-stranded DNA substrates (20bp) spanning the TIR-5 
sequence (Figure 17B).   The results of doing EMSAs on these substrates showed that gp33103 




Figure 19 - gp33103 binding to substrates within TIR-5 
EMSAs showing gp33103 binding to 20 bp substrates spanning the TIR-5 substrate (see Figure 
17B). Binding occurs to the TIR-5.2 fragment containing regions 3 and 4 from DNase I 
footprinting and what we predict to be OR-L.  Protein concentrations are as follows: 1) none 2) 
0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM.  See Table 3 for substrate 
sequences and Table 4 for binding affinities.    
3.3.2.2 End-Deletion Series of Substrates 
We wished to determine whether the ORep half-site present near the Prep promoter was 
indeed an area where gp33103 bound on the left half of the 33-34 intergenic region as the 
footprinting results suggested so we created a series of substrates spanning the 33-34 intergenic 
region that gradually and sequentially removed ~40bp increments of sequence from each end of 
the substrate to be used in EMSAs (Figure 20).  We created these substrates two ways, first with 
sequence being removed from the left (or alternatively viewed as added in from the right side of 
the intergenic region - substrates Mt2-Mt7 – Table 2) and second with sequence being removed 
from the right (or added from the left - substrates Mt8-Mt13 – Table 2).  Our hope with the first 
set of substrates was to determine at which sequence addition gp33103 was able to form more 
complicated binding patterns to draw conclusions as to the nature of these complexes.  The 
second set of substrates were also designed to allow us to draw conclusions on the nature of 
gp33103 complexes, but also to help pinpoint more exactly the location of the second gp33103 




Figure 20 - End-deletion series of substrates 
The sequences and relative positions of the end-deletion series of substrates within the 33-34 
intergenic region are shown.     
We used each of these substrates in EMSAs (Figure 21).  Our results when sequence is 
sequentially added from the right side of the 33-34 intergenic region shows that binding begins 
when sequence containing the 12bp OR site is added (Mt3 substrate).  The binding profile is that 
of protein binding a single site and causing a single mobility shift.  Substrate Mt4 also has a 
relatively simple binding pattern and both Mt3 and Mt4 contain all of OR. However, the relative 
mobilities (Rf) of the major complexes differ (0.69 and 0.55 for Mt6 and Mt5 respectively). 
Although many factors can influence complex mobility, we propose that the stoichiometries of 
both are the same, but that there is a protein-induced DNA distortion influencing complex 
mobility. As more sequence is gradually introduced onto the substrate, we see an increase in the 
number of complexes formed until finally once the entire sequence of the 33-34 intergenic region 
is included, we see the four complexes that are typically formed in the binding profile within this 




Figure 21 - gp33103 binding to end-deletion series of substrates 
BPs gp33103 binds with variable affinities to a series of end-deletion substrates. Substrates were 
PCR amplified from the BPs 33-34 intergenic region using primers located at regular intervals 
from each end to sequentially shorten the 33-34 intergenic region from each end (Table 3). The 
sequences included in each substrate are shown as horizontal black lines either above or below a 
schematic representation of the 33-34 intergenic region. Genes 33 and 34 are represented by blue 
and orange arrows respectively, and OR and ORep are shown in yellow. Protein concentrations are 
as follows: 1) none 2) 0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM.  Protein 
affinities are shown in Table 4. 
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Our results when sequence is added in from the left (Figure 21) show that once the ORep 
6bp half-site is included in the sequence (Mt9), gp33103 is still not binding.  It is not until the 
subsequent 40bp of sequence are added to the substrate (Mt10), which include the adjacent 
Region 2 of DNase I protection (section 3.3.1) that we see gp33103 beginning to bind.  Regardless 
of the absence of OR, binding to substrates Mt10 and Mt11 is relatively weak, and binding to this 
33-promixal part of the site presumably also contributes to complexes formed with the full-
length 33-34 intergenic region. It is not until substrate Mt12 that we see gp33103 binding at a 
similar affinity to wild type with the typical complexes being formed (as determined by Rf).  
Interestingly, the binding patterns seen with the Mt12 and Mt13 substrates are similar, even 
though the 12bp OR is present in Mt13 but absent from Mt12. The affinity for Mt12 is slightly 
reduced compared to that of Mt13 (Table 4), but we assume that the slowest migrating 
complexes (C4) have similar stoichiometries, with each containing gp33103 bound at OR or the 
areas encompassing Region 3 and Region 4 from DNase I footprinting, in addition to binding 
elsewhere in the substrate. Also of note is that one of the Mt13 complexes (C3) appears to be 
absent from the Mt12 substrate, and probably requires the 12bp OR.  
These results showed that gp33103 binds to both the 33- and 34- proximal regions of the 
33-34 intergenic region, but the evidence also strongly suggests that the operator ORep stretches 
beyond the 6bp half-site into a full-sized operator, even though there is not much sequence 
similarity to the full palindrome, and that the 12bp OR operator also stretches further to the left.    
3.3.2.3 Evidence leads to new theory on operator sequences 
Because of the DNase I protection patterns shown in Figure 13, and the results of the 
assays done with the end deletion and TIR series of substrates (Figures 18, 19, 21), we propose 
that the gp33103 binding site at PR spans a larger region than just the 12 bp palindrome, and that 
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this palindrome is equivalent to a half site, of which Region 4 (and perhaps part of Region 3) 
constitute the other half site, not withstanding the sequence dissimilarities (see Figure 22 - all 
substrates together and operator sites marked clearly). We propose the sequence 5’-
GCGCATTTTCCA for OR-L which retains five bases of the 12 bp palindrome (Figure 22). To 
simplify the presentation and discussion of data from here on out, we will refer to the 12 bp 
palindrome as OR-R and the region to the left that includes Region 4 as OR-L (Figure 22) 
reflecting the right and left half sites of OR respectively.  The TIR-5 and TIR-5.2 substrates 
contain OR-L but do not contain OR-R (Figure 22). A plausible explanation is that gp33103 binds as 
a tetramer to OR-L and OR-R independently and at reduced affinity, despite the sequence 
differences. In this model, the tetramer would also have two unoccupied helix-turn-helix DNA 
binding domains, which would be available for binding either to another site within the same 
substrate (perhaps ORep) with introduction of a DNA loop, or by forming intramolecular bridges 
between two different DNA molecules. 
 
 
Figure 22 - Locations of predicted complete operators in the 33-34 intergenic region 
The locations of the left and right half sites of OR and ORep are shown, along with the sequences 
of all substrates used that led to this hypothesis.   
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3.3.3 Binding to partial sites 
As previously mentioned in section 2.3.1.2, BPs gp33103 is known to bind to several additional 
sites within the BPs genomes (97).  We decided to investigate whether there are similar 
complexities to the binding of gp33103 at these sites. The three other instances of sequences 
identical to OR-R are located in small intergenic regions, between genes 5 and 6 (O6), between 
genes 26 and 27 (O27), and between genes 54 and 55 (O55) (Figure 23). We also found a site 




Figure 23 - Map of BPs genome with operators marked 
The BPs genome is shown with black lines indicating positions of operators.   
 
 
To test whether these regions play a role in the phage transcriptional program and are 
subject to repressor control, each was inserted upstream of an mcherry reporter gene and 
transformed into M. smegmatis mc2155. The 5-6, 26-27, 54-55, and 60-61 regions all have 
promoter activity (P6, P27, P55, and P61), although the strengths vary, with P55 being the most 
active, and P27 the weakest (103). Putative promoter elements containing -10 and -35 hexameric 
motifs are predicted for P6, P55, and P61, but not confidently for P27 (Figure 24). The promoter-
reporter plasmids were also transformed into a BPs lysogen and the promoter activities 
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determined. The P6, P27, and P55 promoters are clearly down regulated in a lysogen, presumably 
by gp33103, as is PR (97).  No regulation for either Prep or P61 was observed.  
In view of the hypothesis that the 12 bp palindrome at OR-R corresponds to a half-site for 
gp33103 binding, we examined the other intergenic region sequences for additional sites related to 
OR-R. Interestingly, in all four regions we identified different, but related, sequences that are 
positioned either 5 bp (O6, O27, O61), or 8 bp (O55) away from the other half site, and that differed 
from the palindrome by 2-5 base pairs.  This finding was consistent with the 12 bp palindrome 
constituting just one of two half sites. From here on out we will refer to the left and right halves 
of each of these as O6-L and O6-R, O27-L and O27-R, O55-L and O55-R, and O61-L and O61-R for O6, 
O27, O55 and O61 respectively (Figure 24).  
 
 
Figure 24 - Sequences of all BPs operators within their respective promoter regions 
Sequences of the intergenic regions containing promoters with operators are shown.  Operator 
half sites are labeled.  Half sites highlighted in yellow indicate full sequence identity to the 12bp 
palindrome.  Sites highlighted in orange are half sites that are not full palindromes, but still show 
an interaction with gp33103.  Sites highlighted in pink do not bind gp33103 alone.  Sites 
highlighted in gray have not been tested.   
 
To explore each of these sequences in more detail, we created two types of substrates for 
each operator.  The first had the half site containing the 12bp palindrome intact with the second 
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half site mutationally ablated to have no sequence identity with the palindrome, which 
theoretically would prevent gp33103 from binding to that half site as it normally would.  The 
second had the non-palindromic half site separated from its native sequence to see if gp33103 
binds it without the full palindrome present on the same substrate.  For reference, binding assays 
done with OR and ORep are shown in Figure 25, however these particular substrates were created 
before the theory of operators consisting of two half sites and are therefore not as informative as 
the other operator substrates.   
 
Figure 25 - Substrates testing ORep and OR 
EMSAs show binding profiles of gp33103 to the substrates shown in the diagrams.  Protein 
concentrations were as follows: 1) none 2) 0.16 μM 3) 0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 
7) 54 μM.   
 
 
Gp33103 binds within the 5-6 intergenic region where studies by Oldfield et al. (97, 103) 
have established the presence of a late lytic promoter.  This promoter is downregulated in a 
lysogen, so we know that gp33103 plays a role in this region during lysogeny.  Along with a full 
12bp palindromic half site (O6-L), we found a partial binding site in this region that differs from 
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the palindrome by 3 base pairs (O6-R) (Figure 24).  When gp33103 binds to a 45bp substrate 
where O6-R is mutationally ablated, a single protein-DNA complex is formed (Figure 26B).  A 
binding assay done on this O6-R site while isolated from its native sequence by placing it in a 
non-native sequence context shows that there is no binding (Figure 26C, Table 3).  This shows 





Figure 26 - gp33103 binding to the O6 operator 
EMSAs show binding profiles of gp33103 to the substrates shown in the diagrams.  Gp33103 binds 
to O6-L, but not O6-R alone.  Protein concentrations were as follows: 1) none 2) 0.16 μM 3) 0.54 
μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM.      
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Gp33103 binds within the 26-27 intergenic region (Figure 27A) where studies by 
Broussard et al. predicted that no promoter was present (Figure 24), but since this intergenic 
region lies upstream of the lysis cassette, we theorized that gp33103 may still play a role in 
preventing read-through transcription.  In her doctoral dissertation, Lauren Oldfield showed that 
the 26-27 intergenic region does have very slight promoter activity, and that this weak promoter 
is downregulated in a lysogen, however no promoter sequences have been identified.  This 
evidence suggests that gp33103 indeed plays a role in this region during lysogeny.   
 
 
Figure 27 - gp33103 binding to O27 
EMSAs show binding profiles of gp33103 to the substrates shown in the diagrams.  Gp33103 binds 
to both O27-L, and O27-R alone.  Protein concentrations were as follows: 1) none 2) 0.16 μM 3) 
0.54 μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM.    
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Along with a full 12bp palindromic half site (O27-R), we found a partial binding site in 
this region that differs from the palindrome by 2 base pairs (O27-L) (Figure 24).  When gp33103 
binds to a 45bp substrate of native 26-27 intergenic region sequence where O27-L is mutationally 
ablated, a single protein-DNA complex is formed (Figure 27B).  A binding assay done on this 
O27-L site while isolated from its native sequence by placing it in a non-native sequence context 
shows that there is slight binding (Figure 27C; Table 3), which could explain why the binding 
affinity of gp33103 to the 26-27 intergenic region is stronger than to any other intergenic region 
tested.   
If gp33103 binds strongly to both half sites rather than just one as the binding assays 
suggest, perhaps the role of gp33103 in this region is more important than in other operators.  This 
shows us that the two base pairs that differ from the palindrome are not as necessary for binding 




Figure 28 - gp33103 binding to O55 
EMSAs show binding profiles of gp33103 to the substrates shown in the diagrams.  Gp33103 binds 
to O55-L, but not O55-R alone.  Protein concentrations were as follows: 1) none 2) 0.16 μM 3) 0.54 
μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM.    
 
When gp33103 binds within the 54-55 intergenic region where studies by Oldfield et al. 
(97, 103) have established the presence of a lytic promoter (Figure 24), a larger number of 
complexes are formed than with any of the other non-PR intergenic regions (Figure 28A).  This 
promoter is downregulated in a lysogen, so we know that gp33103 plays a role in this region 
during lysogeny.  Along with a full 12bp palindromic half site (O55-L), we found a partial binding 
site in this region that differs from the palindrome by 3 base pairs (O55-R).  When gp33103 binds 
to a 45bp substrate where O55-R is mutationally ablated, a single protein-DNA complex is formed 
(Figure 28B).  A binding assay done on this O55-R site while isolated from its native sequence by 
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placing it in a non-native sequence context shows that there is no binding (Figure 28C, Table 3).  
This shows us that some or all of the three base pairs that differ from the palindrome are 
necessary for binding; however these results don’t help us understand why there are more 
complexes in the binding profile of gp33103 within the 54-55 intergenic region than there are in 
other intergenic regions.  
 
 
Figure 29 - gp33103 binding to O61 
EMSAs show binding profiles of gp33103 to the substrates shown in the diagrams.  Gp33103 binds 
to O61-R, but not O61-L alone.  Protein concentrations were as follows: 1) none 2) 0.16 μM 3) 0.54 
μM, 4) 1.6 μM, 5) 5.4 μM, 6) 16 μM, 7) 54 μM.    
 
The 60-61 intergenic region contains a promoter for a three gene operon (103).  Within 
the predicted promoter region we found two operator half sites, one with 2bp differences from 
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the palindrome (O61-R) and one with 5bp differences (O61-L) (Figure 24).  When we tested 
gp33103 binding to the two half sites only O61-R showed binding (Figure 29B).  Both partial sites 
contain the same final two base pair substitutions and the left half site also contains three other 
base pair substitutions.  This accumulation of differences from the 12bp palindromic sequence is 
probably why there is no binding to O61-L (Figure 29C).  The right half site, however, has a 
binding profile similar to that of other fully palindromic operator half sites and gp33103 binds to 
this site with a comparable affinity to those sites (Table 4), suggesting that the two base pair 
substitutions are not very important for binding. Despite the promising binding results and the 
presence of a promoter near the O61 operator, fluorescence reporter assays have shown that the 
P61 promoter is not downregulated in a lysogen, so although gp33103 can bind to O61, it may not 
be exerting an effect at that location in vivo. It is entirely possible, however, that if gp33103 is 
capable of preventing read-through transcription, that it could do so at this operator.   
 
3.3.4 Clear plaque mutant analysis 
In the studies done by Broussard et al., multiple repressor-insensitive and clear-plaque phage 
mutants were discovered and sequenced.  Sequencing results showed that all of these mutants 
had either mutations within the repressor gene, gene 34, or mutations within the 33-34 intergenic 
region (Figure 30 – Table 3).  This evidence led to the hypothesis that the gene 32, 33, 34 




Figure 30 - Locations of BPs repressor insensitive mutations that map to the 33-34 intergenic region 
Locations of the mutations in each substrate (see Table 3).  
 
Most of the mutations mapped within the repressor gene itself (97), which is not 
surprising since the repressor is necessary for maintenance of lysogeny.  For the mutations that 
mapped within the 33-34 intergenic region, Clr1 has a T29336C base pair substitution in the -10 
element of Prep which strongly reduces the promoter’s activity, and without proper expression of 
the repressor gene, lysogeny cannot occur. A binding assay done on this mutant shows a similar 
binding profile as wild type (Figure 31).  Clr4, Clr6, and Clr8 have base pair substitutions in the 
-10 or -35 promoter elements of PR.  The Clr4 and Clr8 base pair substitutions have been shown 
to lead to an upregulation in promoter activity, however the Clr6 mutation does not (97, 102).  
With PR upregulated in the Clr4 and Clr8 mutants, the genetic switch is pushed toward lytic 
growth.  The Clr6 point mutation is, however, located within OR-L and could influence gp33103 
activity within OR.  Binding assays done with these three mutants show that Clr 8 has a binding 
profile similar to wild type, Clr6 has an early appearance of the C1 complex compared to wild 
type but all other complexes appear at similar protein concentrations, and Clr 4 has an earlier 




Figure 31 - gp33103 binding to substrate variants of the 33-34 intergenic region derived from 
repressor-insensitive mutants 
(A) Locations of the mutations in each substrate (see Table 3). (B) Binding profiles of gp33103 to 
each 33-34 substrate. The concentrations of protein are as follows: 1) none, 2) 0.16μM, 3) 
0.54μM, 4) 1.6μM, 5) 5.4μM, 6) 16μM, 7) 54µM. Protein affinities are shown in Table 4.  
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Two mutants described in section 2.3.2.2 (102a and 102e) were shown to have point 
mutations in OR-R that reduce the affinity of gp33103 by about 3-10-fold (depending on specific 
DNA substrate used), which allows expression of the early lytic genes that outcompete the 
repressor and lead to lytic growth (Figures 7, 31).  Six other mutants have more substantial 
sequence rearrangements.  Mutant 102j has a 151bp inversion that flips the direction of Prep and 
also removes the 5’ end of the repressor gene from the 3’ end.  With the repressor gene 
interrupted and Prep facing the opposite direction, lysogeny cannot occur because gp32 is not 
expressed, and no functional repressor can be made.  The binding profile of gp33103 to 102j 
shows similar binding affinity as to a wild type substrate, but only complexes C3 and C4 are 
formed (Figure 31).  Mutant 127b has a 151bp deletion that removes the 5’ end of the repressor 
gene, Prep, and OR-L.  Without the Prep or the 5’ end of the repressor gene, gp32 cannot be made 
and no functional repressor can be synthesized.  The binding profile of gp33103 to this mutant 
reflects the removal of ORep and OR-L, as C1 becomes the major complex and a moderate amount 
of C2 complexes are made (Figure 31).  127d, 127e, and 102k have duplications within OR-R, 
which presumably have an effect on gp33103 binding and affect PR repression in a lysogen.  
These mutants have similar binding profiles as wild type, however some of the faster-moving 
complexes (C1 and C2) are missing (Figure 31).  Mutant 127c has a duplication within the gene 
34 open reading frame that probably affects the proteins’ function and could allow it to more 
strongly counteract the repressor’s actions.  The binding profile of gp33103 to this mutant shows a 
wild type binding profile (Figure 31).  Clr 5 is the hardest mutant to explain.  It is a single base 
pair substitution in the central part of the 33-34 intergenic region that does not interfere with any 
promoter or operator sequences.  Binding assays done on this mutant shows a binding profile 




In this chapter we have discussed the experiments that led to identification of the true operator 
sequence being composed of two 12bp half sites separated by either 5bp or 8bp, with a 5bp 
spacer being the most common.  DNase I footprinting assays showed areas of protection near the 
Prep promoter, and the PR promoter.  Interestingly, the footprinting showed a large area of 
protection extending toward the center of the 33-34 intergenic region where we would not have 
predicted the protein bound.  Binding assays with the TIR series of substrates confirmed that 
gp33103 does indeed bind to DNA to the left of OR, and the end-deletion series of substrates 
showed that inclusion of the area to the left of OR led to a similar binding phenotype as if OR 
itself were present (Mt12).  In light of these data we proposed that OR is not just a 12bp site, but 
that it extended further into the 33-34 intergenic region.   
We did not hypothesize the presence of a second half site until we tested the data of the 
other intergenic regions (5-6, 26-27, 54-55) and their operators (O6, O27, O55).  In each of these 
regions we found a second partial site that contained 2-3bp departures from the palindrome.  We 
also found two partial sites in the 60-61 intergenic region and found the operator O61.  Although 
OR and ORep did not have sites with such similar sequence identity (>75% identical to 
palindrome), we did find some similar sequences.  The new OR and ORep are annotated correctly 
in the diagram in Figure 32.   How this knowledge allows us to better understand how gp33103 





Figure 32 - Locations of ORep and OR relative to Prep and PR 
Diagram showing the sequence of the 33-34 intergenic region.  Operators are labeled and half 
sites are highlighted in yellow.  Promoter sequences are in green text with transcription start sites 
indicated with +1.   
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4.0  HOW GP33103 FUNCTIONS TO PREVENT TRANSCRIPTION OF LYTIC 
GENES      
Work done in this section was published in the following publication: 
Villanueva, V.M., Hatfull, G.F., September 2015.  An Unusual Phage Repressor 
Encoded by Mycobacteriophage BPs. PLoS One, Volume 10:e0137187.   
 
4.1 INTRODUCTION 
Repressor proteins can function in a variety of ways.  The first and most obvious way a repressor 
can block lytic gene expression is by promoter occlusion.  The presence of repressor binding to 
its operator(s) within the promoter elements sterically prevents the bacterial RNA polymerase 
from binding (177, 178).  Another way is by binding within or near a promoter and changing the 
secondary structure of the DNA such that the RNA polymerase cannot bind, or if it does, the 
secondary structure does not let the polymerase proceed to elongate the transcript (134, 136).  A 
third way is with direct interaction with RNA polymerase to either prevent promoter recognition 
or prevent transcript elongation (179).  In this section we describe the experiments done to 
identify how the repressor exerts its function.  We show that gp33103 likely exerts its effect via 
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DNA bending and that the spacer region between operator half-sites is important for proper 
bending.   
4.2 MATERIALS AND METHODS 
4.2.1 DNA binding assays 
Electrophoretic mobility shift assays were performed as described previously in section 2.3.2 
with minor changes.  Substrates resulting from PCR or synthetic oligonucleotides were prepared 
as previously described.  Substrates resulting from digested DNAs were first treated with calf 
intestinal phosphatase (NEB) to remove 5’ phosphates and then run on a 0.8% agarose gel and 
extracted using a GeneJet gel extraction kit from Fermentas according to manufacturer 
recommendations.  The concentration of these substrates and subsequent radiolabeling and use in 
EMSAs were performed as previously described.  The substrates used in this chapter are listed 
below in Table 5. 




33-34 intergenic region (226bp) Fwd: TCCGGCCCATATCGAATGCTTGCGACAT Rev: CGGTTGGGGTCATGTGCACCAACAT 
33-34 intergenic region (366bp) Fwd: GTTCTTCTTGCTTCAAACCAGCTTCAAGG Rev: GTGTAGTGATCGCTTCGGAATGTCATGC 2 half sites 5bp apart CACCGACGCGACATATGTCGACTGACGACATATGTCGCAGCCTGG  Left half site ablated (5bp apart) CACCGACGAAGTGCCACGATACTGACGACATATGTCGCAGCCTGG Right half site ablated (5bp CACCGACGCGACATATGTCGACTGAAAGTGCCACGATCAGCCTGG  
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apart) 2 half sites 8bp apart ACCGACGCGACATATGTCGACGCTTGACGACATATGTCGCAGCCT  Left half site ablated (8bp apart) CCGACGAAGTGCCACGATACGCTTGACGACATATGTCGCAGCCTG  Right half site ablated (8bp apart) CCGACGCGACATATGTCGACGCTTGAAAGTGCCACGATCAGCCTG  
 
4.2.2 Preparation of pBend2 plasmid for use in bending assays 
4.2.2.1 Creation of plasmids  
The 33-34 intergenic region was PCR amplified from a BPs lysate using primers 5’-ATA TCG 
AAT GCT TGC GAC ATT CTA GAG ATT GTA TGT AC -3’ and 5’- GTC ATG TGC ACC 
AAC ATG TCG ACT ATG TCG T  3’, which amplified the region with a SalI recognition site at 
the 5’ end of the gene and a XbaI recognition site at the 3’ end.  This substrate was run on a 0.8% 
agarose gel to check its purity, digested with SalI and XbaI (Fermentas fast digest enzymes), 
PCR purified using a GeneJet PCR purification kit from Fermentas, and was ligated using an 
Epicentre Fast-Link DNA ligase kit into the pBend2 vector (pLC3) that was linearized with SalI 
and XbaI, phosphatase treated (calf intestinal phosphatase – NEB), and run on a 0.8% agarose 
gel and gel extracted using a GeneJet gel extraction kit from Fermentas.   The resulting plasmid, 
pVMV21, was transformed into chemically competent NEB5-α cells (New England BioLabs) 
and colonies were picked into Luria-Bertani Broth (Difco) with Kanomycin selection.  Plasmids 
were extracted from overnight cultures using a GeneJet plasmid miniprep kit from Fermentas 
according to manufacturer recommendations.  The plasmids were sent to GeneWiz for 
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sequencing according to company instructions and the plasmid with the correct sequence was 
stored at -20°C.   
pVMV22 was created in a similar manner to pVMV21, except that rather than PCR 
amplification, the insert was a synthetic oligonucleotide engineered with OR-R in the center of the 
substrate and SalI and XbaI restriction endonuclease sites flanking the 12bp sequence.  
Complimentary synthetic oligonucleotides were ordered from IDT and annealed according to the 
previously described protocol.  The double stranded DNA substrate was digested with SalI and 
XbaI Fermentas fast digest enzymes and gel extracted with a GeneJet gel extraction kit from 
Fermentas according to manufacturer protocol.  This was inserted into a linearized pBend2 
vector and the plasmid with correct sequence was stored.   
4.2.2.2 Preparation of substrates from pVMV21 and pVMV22 
pVMV21 and pVMV22 were subjected to various enzyme cleavage reactions.  For each 
digestion reaction, ~500ng of plasmid DNA was digested with 2 units of the corresponding 
enzyme.  The resulting digested pieces were then treated with phosphatase and gel extracted.  
These substrates were radiolabeled and used in EMSAs.  The restriction enzymes used to create 
each substrate are: MluI, BglII, NheI, StyI, SpeI, XhoI, EcoRV, SmaI, NRuI, NcoI, BamHI.   
4.2.3 RNA Polymerase Purification and Binding Assay Methods 
4.2.3.1 Purification of RNA polymerase 
The M. smegmatis RNA polymerase core enzyme was purified as previously described 
(180, 181).  Briefly, a 1L M. smegmatis mc2155 culture was grown to saturation in 7H9 broth 
(difco) supplemented with CB/CHX/ADC/Tween80.  The pellet was spun down and frozen.  The 
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cell pellet was thawed and 5 g of cells were resuspended in 15 mL Buffer A (50mM Tris, pH 7.9, 
0.5 mM EDTA, 50 mM NaCl, 5% glycerol, 0.1 mM DTT) with 260 µg lysozyme per mL and 
incubated on ice for 20 min.  200 µl of 10% sodium deoxycholate was added and the mixture 
was incubated on ice for another 10 minutes.  The cells were sonicated with a VirSonic sonicater 
at 30% power output 10 times for 30 sec with 2 minutes of ice in between bursts.  15 mL Buffer 
A was added to the cells, mixed, and then the cells were centrifuged for 10 minutes at 10,000 
rpm.  The supernatant was PEI precipitated (182) by adding 900 µl 10% PEI, mixing for ten 
minutes at 4°C, and centrifuging 10 min at 6,000 rpm.  Pellet was washed by adding 20 mL 
Buffer A + 0.3 M NaCl and resuspended using a handheld Dounce homogenizer, then spun for 
ten minutes at 6,000 rpm.  The polymerse was eluted from the pellet by resuspending 20 mL 
Buffer A + 1 M NaCl and centrifuging for ten minutes at 6,000rpm.  To 20mL supernatant, 
added 7.6 g ammonium sulfate for an ammonium sulfate precipitation (182).  The mixture was 
incubated at 4°C with rocking for 10 min and then spun down at 6,000 rpm for 10 min.  The 
pellet was dissolved in 20 mL TE (50mM Tris-HCl pH 7.9, 0.5mM EDTA), centrifuged at 6,000 
rpm for ten minutes, and the supernatant was collected and kept on ice.   
Meanwhile, 2 mL of MAb 8RB13-Sepharose (A kind gift from the Richard Burgess 
laboratory (183-185)) was washed on a fritted glass funnel with 20 mL TE + 0.15 M NaCl.  This 
was then incubated with the supernatant fluid containing the RNA polymerase and mixed end-
over-end for 1hr at 4°C.  At room temperature, the mAB 8RB13-Sepharose was collected on the 
fritted glass funnel, washed with 20 mL TE + 0.15 M NaCl, poured into a disposable BioRad 
column and washed with 5mL TE + 0.5 M NaCl.  The RNA polymerase was eluted with 10 mL 
TE + 0.75 mM Ammonium sulfate and 40% propylene glycol (this step must be done at room 
temperature) and fractions were collected.  DTT was added to each fraction (0.1 mM final 
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concentration) and fractions were pooled and dialyzed into storage buffer (Buffer A with 50% 
glycerol).  Purified RNA polymerase core enzyme was stored at -20°C.   
4.2.3.2 Purification of SigA and reconstitution of RNA polymerase holoenzyme 
Creation of pVMV36 
To create pVMV36, The Mycobacterium smegmatis sigA gene, formerly mysA, (125, 186, 187) 
was PCR amplified using primers 5’ – TTT TTT CAT ATG CTG ATC TCT CAG CGT CCC 
AC – 3’ and 5’ – TTT TTT AAG CTT AAG CTG CTC GGT CTC GGC GTA GT – 3’ from 
purified wild type M. smegmatis mc2155 DNA, taken with permission from a DNA extraction 
performed by Zaritza Petrova in the Hatfull lab.  The gene was amplified with NdeI (5’ end) and 
HindIII (3’ end) restriction enzyme recognition sequences.  The resulting PCR product was 
digested with NdeI and HindIII Fermentas Fast Digest Enzymes and gel extracted using a 
GeneJet gel extraction kit from Fermentas according to manufacturer protocol.  This substrate 
was ligated into a NdeI/HindIII linearized, phosphatase-treated (NEB CIP), gel extracted pET21a 
vector (Invitrogen), which has an IPTG-inducible promoter and introduces a C-terminal histidine 
tag to the expressed protein.  The ligation was transformed into chemically competent NEB5-
alpha cells (NEB) and colonies were picked into LB broth (Difco).  The resulting cultures were 
miniprepped using a GeneJet Plasmid miniprep kit from Fermentas according to manufacturer 
protocol to extract the plasmids.  Plasmid samples were sent to GeneWiz for sequencing 
according to company guidelines and the correct plasmid was stored at -20°C.   
Expression and Purification of SigA 
 78 
pVMV36 was transformed into RIPL chemically competent cells (gift from the VanDemark 
laboratory) and colonies were picked into 5mL LB broth (Difco) with selection and grown 
overnight at 37°C.  1L of media was inoculated at an OD600 of 0.01-0.05 and grown until 
cultures reached an OD600 of 0.4-0.6. His-tagged SigA expression was induced with 1 mM IPTG 
at 17°C overnight. Cells were pelleted and frozen at -80°C. Thawed cell pellets were 
resuspended in 5mL per gram of Buffer A (50mM Tris, pH 7.9, 0.5 mM EDTA, 50 mM NaCl, 
5% glycerol, 0.1 mM DTT) and lysed in 200 mL fractions by sonicating 10 times for 10 sec at 
30% output with 30 sec of cooling on ice in between bursts. Pooled cell lysates were cleared by 
centrifugation at 30,000 x g for 40 min at 4°C. His-tagged SigA was extracted from the soluble 
cell lysate using nickel affinity chromatography (Ni-NTA resin, Invitrogen) and fractions were 
evaluated for protein purity and fractions with pure protein were pooled and dialyzed into a 
storage buffer (50mM Tris, pH 7.9, 0.5 mM EDTA, 50 mM NaCl, 50% glycerol, 0.1 mM DTT) 
and stored at -20°C. 
4.2.3.3 Western Blot analyses 
Western blots were performed as previously described (102).  Briefly, protein samples were run 
on an SDS polyacrylamide gel and transferred to a PVDF membrane (BioRad) using a BioRad 
wet transfer apparatus according to manufacturer recommendations.  The membrane was blocked 
with TBS + 5% milk for 1-3 hours, washed with TBST three times for 5min, probed with 
primary antibody in TBS + 5% BSA (8RB13 or 4RA2 – both gifted from the Richard Burgess 
laboratory) at a 1:5000 dilution for 30-60min, washed with TBST three times for 5min, and 
probed with anti-mouse AP-conjugated secondary antibody in TBS + 5% milk for 30min.  After 
2 quick rinses with TBS, a BCIP/NBT Substrate Kit (Invitrogen) was used to induce a 
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colorimetric reaction from the secondary antibodies and presence or absence of probed protein 
was detected.   
4.2.3.4 DNA Binding Assay using agarose gel electrophoresis 
A binding assay using a large protein complex can be too large to fit through the matrix of a 4-
5% native gel, so in these instances a variation of a DNA binding assay can be done on an 
agarose gel.  In this assay, no non-specific carrier DNA is added and the binding substrates are 
not radiolabeled.  Increasing concentrations of protein are added to a constant concentration of 
substrate DNA in a binding buffer containing 20 mM Tris pH 7.5, 10 mM EDTA, 25 mM NaCl, 
10 mM spermidine, and 1 mM DTT for a total volume of 10 µl. Reactions were incubated at 
room temperature for 30 min and the resulting protein DNA complexes were resolved on a 1% 
agarose gel.  The agrose gel was stained with 500mL 1x TBE and 5µl Ethidium Bromide (sigma) 
for 15 minutes, and destained for 20 minutes in 1x TBE.  A BioRad geldoc XR+ geldoc imaging 
system was used to detect bands. 
4.3 DNA BENDING 
After theorizing in various sections of previous chapters, we decided to conclusively test if one 
of the complexes present in the binding profile of gp33103 to the 33-34 intergenic region was due 
to gp33103 affecting the structure of the DNA and bending it.  To look at this we utilized the 
pBend2 plasmid ((188-190) a kind gift from the laboratory of Andrew VanDemark), which 
contains two identical sets of restriction endonuclease recognition sites surrounding a unique 
cloning site.  Cutting with each enzyme in succession results in multiple substrates of equal 
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length with the unique site in the middle shifting from one end of the substrate, toward the 
middle and on to the other side of the substrate (191).  In this assay we cloned both OR-R 
(pVMV22) and the 33-34 intergenic region (pVMV21) into the unique cloning site and cleaved 
the plasmid with each enzyme in parallel reactions.  Since bent DNA has a lower mobility 
through a gel than unbent DNA, we ran each substrate on a gel with gp33103 at a concentration at 
which it binds ~50% of the DNA (5.4µM) and looked for an upward shift when the unique site 
was located in the middle of the substrate.   
4.3.1 Gp33103 does not bend DNA at the OR-R site alone 
We decided to check if gp33103 is able to bend DNA if only OR-R is present and not the rest of the 
33-34 intergenic region so we cloned the 12bp OR-R into the unique cloning region of pBend2, 
cut the various substrates from the plasmid, and performed DNA binding assays with each 
substrate (Figure 33).  The results on the gel show that gp33103 is unable to bend the DNA when 
OR-R is present by itself.  What this suggests is that there are other sequences present in the 33-34 




Figure 33 - gp33103 does not bend DNA at OR-R 
The 12bp of OR was cloned into plasmid pBend2 (191) using unique restriction enzyme sites SalI 
and XbaI to create pVMV22. Equal-sized fragments of DNA were excised from pVMV22 with 
OR located at different positions relative to the edge of the probe by cleaving with appropriate 
enzymes. BPs gp33103 (0.54μM) was incubated with each radiolabeled probe and run on a native 
polyacrylamide gel. The only gp33103-DNA complex (C1) does not show any differences in 
relative mobility with different substrates.   
 
4.3.2 Gp33103 bends DNA within the 33-34 intergenic region 
When we tested the full 33-34 intergenic region for binding using pVMV21, what we saw on the 
gel was not only a change in mobility as the 33-34 intergenic region reached the center of the 
substrate, but a continuing upward shift that did not lose mobility when the 33-34 intergenic 
region reached the other end of the substrate (Figure 34).  Only complexes C2 and C3 show a 
change in mobility; complex C1 does not.  The simplest explanation for this is that bending is 
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occurring at OR, not ORep, and due to the location of OR at the right-most end of the 33-34 
intergenic region, the operator never makes it past the center of the substrate, and therefore we 
don’t see the decreasing mobility corresponding to the bend migrating to the other end of the 
substrate (192). The C1 complex could be the interaction between gp33103 and ORep.  No intrinsic 
bending of 33-34 intergenic region was observed (data not shown).  The magnitude of the bend 
(191) is estimated to be approximately 48°, which is consistent with gp33103 being bound and 
introducing a DNA distortion as a tetramer to OR-L and OR-R.  
 
 
Figure 34 - gp33103 bends DNA within the 33-34 intergenic region 
The 33-34 intergenic region was cloned into plasmid pBend2 (191) using unique restriction 
enzyme sites SalI and XbaI to create pVMV21. Equal-sized fragments of DNA were excised 
from pVMV21 with the insert located at different positions relative to the edge of the probe by 
cleaving with appropriate enzymes. BPs gp33103 (5.4μM) was incubated with each radiolabeled 
probe and run on a native polyacrylamide gel. The results suggest that a bend of about 48° is 
introduced into the major complex (C4) by gp33103 binding. 
 83 
4.4 DNA LOOPING 
We wondered if one of the complexes present in the binding profile of gp33103 to the 33-34 
intergenic region was due to gp33103 binding to multiple areas and interacting, thus creating a 
and Inter-DNA bridge, or DNA loop, as has been demonstrated with lambda cI (192, 193).  To 
test this we created two different sized substrates (366bp and 226bp; Table 5), both containing 
the 33-34 intergenic region centered.  We compared the binding profiles of gp33103 to each 
substrate separately, and then of gp33103 binding to both substrates present in the same reaction 
(Figure 35). If one of the complexes is due to looping, we would expect to see a complex present 
when both sized substrates are added together, that is not present when gp33103 binds to each 




Figure 35 - gp33103 does not create inter-DNA bridges 
To determine if intermolecular DNA bridges are formed by gp33103, two different sized 
fragments of DNA containing the 33-34 intergenic region (366 bp and 256 bp) were PCR 
amplified and radiolabeled (Table 5). The leftmost six lanes contain only the 366 bp substrate, 
the middle six lanes contain only the 256 bp substrate, and the rightmost six lanes contain both 
substrates. Complexes formed with each substrate are indicated by arrows. The concentration of 
protein in each series of substrates is 1) none, 2) 0.54μM, 3) 1.6μM, 4) 5.4μM, 5) 16μM, 6) 54 
μM. 
 
We did not see any such bands and therefore concluded that gp33103 is unable to facilitate loop 
formation within the 33-34 intergenic region (Figure 35).  This assay has not necessarily ruled 
out binding between regions of the genome that contain operators, even though both substrates 
contained a complete OR sequence and a bound gp33103 tetramer was unable to interact with 
another bound gp33103 tetramer.  This assay also does not rule out the formation of hairpin-like 
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structures within the same DNA fragments that do not interact with neighboring strands, even 
though bending assays do not support the hypothesis of gp33103 bending DNA at a magnitude 
necessary for protein bound at ORep and OR to interact.   
4.5 SPACER EFFECT ON OPERATOR FUNCTION 
O6, OR, O27, and O61 each contain half-sites that are 5bp apart.  O55 and ORep on the other hand, 
contain half-sites that are 8bp apart.  We hypothesized that spacer length has an effect on 
gp33103’s ability to bend DNA at these operator sites.  We created a series of 42 bp synthetic 
oligonucleotide substrates, each containing two 12 bp palindromic sequences spaced either 5 bp 
or 8 bp apart (Figure 36). We also made derivatives of these in which either the left or right half 
site was mutationally ablated, and examined gp33103 binding to these substrates.  
 
Figure 36 – gp33103 binds to two adjacent 12bp palindromes 
(A) and (B) EMSAs showing gp33103 binding to substrates containing two 12bp palindromic half 
sites (yellow boxes) spaced either 8 bp (A) or 5 bp apart (B). Substrates in which one half site is 
mutationally ablated is shown as a white box.  
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With a 5 bp spacer, BPs gp33103 binds to form a single complex that has a slower 
mobility than those formed when each of the half sites is ablated (Figure 36). Their affinities are 
not greatly different suggesting a lack of cooperativity, and we propose that each complex 
contains a gp33103 tetramer bound to DNA, but that the presence of two 12 bp palindromes 
enables the protein to correctly dock at each half site and induce a DNA bend, whereas the single 
half-site substrates do not.  
When substrates with an 8 bp inter-site spacing are tested, two complexes are formed, 
one with similar mobility to the single half-site substrates, and a slower one that migrates 
similarly to the 5 bp spaced substrate (Figure 36). We propose that the larger spacing disfavors 
proper docking of gp33103 to its DNA sites, resulting in a mixture of two complexes, one that is 
properly docked and the DNA is bent, and one in which only one half site is engaged and the 
DNA is not bent.   
4.5.1 Changes in PR spacer length affect gp33103 action in vivo, not in vitro  
Taking a closer look at where the operators we’ve confirmed are present with respect to the 
nearby promoters, we drew some conclusions about possible mechanisms of repression.  Except 
for P27, which does not have confidently predicted -10 and -35 motifs, all BPs operators have at 
least one half site that covers part or all of a predicted -10 or -35 motif.    
Usually operators are located over one of the promoter elements (194), so this could be 
indicative of a promoter occlusion mechanism of action, or also, due to the DNA bending we see 
in section 4.3.2, a change in DNA structure could be the cause of RNA polymerase not binding.   
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Some data that Lauren Oldfield collected has shed some light on another possible 
mechanism of action for gp33103 repression.  In her studies of the PR promoter, she fused PR to a 
mCherry reporter gene and expressed it both in wild type M. smegmatis mc2155 and in a BPs 
lysogen of M. smegmatis. Wild type PR expressed mCherry in wild type M. smegmatis, but 
expression was dramatically reduced in a BPs lysogen, as expected.  She created various 
mutations looking for an effect on promoter strength and measured the bacteria for mCherry 
expression by quantifying the fluorescence.   
In wild type PR, the spacer length is 18 base pairs and she saw expression of mCherry in 
wild type M. smegmatis, but decreased expression in a lysogen (Figure 37A/B).  When she 
added one basepair upstream of OR-R, but before the -35 motif, she saw decreased expression 
from PR in wild type M. smegnatis, but no change in the lysogen’s ability to repress the promoter 
(Figure 37A/B).  When she removed one or two base pairs between OR-R and the -35 element, 
however, she saw that while there were some changes in WT M. smegmatis expression, there 
were markedly less decreases in expression in the lysogen.  This means that the repressor in the 
lysogens is unable to block this lytic PR promoter as effectively when OR-R is closer to the -35 




Figure 37 - gp33103 binding to various promoter mutants 
(A) Shows the locations of the base pairs that Lauren Oldfield added and removed.  (B) Shows 
the florescent reporter assays she did in which plasmids with PR (with or without mutations) 
driving mCherry expression were transformed into wild type (blue) and BPs lysogens (red) of 
Mycobacterium smegmatis.  Her result showed dramatic de-repression effects in vivo as a result 
of removing base pairs from the PR spacer.  In (C) EMSAs were done on substrates containing 
just the promoter sequence and showed that the base pair deletions had no effect on binding.   
 
 89 
4.5.2 Gp33103 binds similarly when half-sites are spaced very close or very far apart 
To test whether this effect was due to an inability of gp33103 to bind to OR, we created a 
series of substrates containing just the promoter sequence from the left end of the -35 motif to 
the right end of the -10 motif.   These substrates were created before the hypothesis of OR 
consisting of two 12bp half-sites, so only 6bp of OR-L are included.  The synthetically engineered 
substrates had a wild type spacer length, and either one or two base pairs missing from the 
spacer, reflecting the mutations made in the data from Oldfield and Hatfull (Figure 37C).  
Gp33103 binds just as well to each of the promoter mutants.   
Only one complex is formed when gp33103 binds to these substrates, leading us to believe 
that this complex consists of a gp33103 tetramer binding to OR-R, but not bending DNA, as OR-L is 
not fully present.  We wondered how close (or far) the operator half-sites could be and still bend 
DNA.   
To look at this, we created two 60bp oligonucleotide substrates that had two 12bp 
operaters either 2bp apart, or 23bp apart (Figure 38).  When gp33103 binds to each of these, it 
binds with similar binding profiles, which is unexpected.  Based on results from Figure 36, 
Gp33103 binding to the operator with the 2bp spacer would presumably have a binding profile 
indicating either a tetramer bound to the DNA substrate, or a tetramer bound and bending the 
DNA substrate.  We do see two major complexes being formed, as we do with an 8bp spacer, 




Figure 38 - gp33103 binding to two half sites with varying spacer regions 
EMSAs were performed on 60 bp synthetic oligonucleotide substrates (Table 5) containing two 
12bp palindrome half sites separated by 2 or 23bp.   
 
Curiously, when the half-sites are 23bp apart, we see a very similar binding profile with 
two major complexes being formed, although the faster-moving complex looks slightly more 
dominant (Figure 38).  The best explanation for what is happening is that the faster-moving 
complex is a single tetramer bound to one of the two half sites and the slower moving substrate 
corresponds to both half-sites being occupied.  Due to the relative mobilities of the slower 
moving complex between the 2bp and 23bp spacer substrates being the same, it is unlikely that 
the complexes of bent DNA and DNA with two tetramers bound run at the same mobility.  
Therefore, we propose a second theory for what could be happening at the operator sites.  
Gp33103 could be binding as a tetramer to each half-site and with the correct spacing, interacting 
and bending DNA, but without the correct spacing, just binding without bending.   
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4.6 INTERACTION WITH RNA POLYMERASE 
Some repressors, such as lambda cI, are capable of directly interacting with RNA polymerase to 
exert an effect (195).  In the example of lambda, CI interacts with the alpha subunit of the RNA 
polymerase to enhance transcription of its own gene during lysogeny (195).  In other systems, 
repressors interact with RNA polymerase in solution to prevent it from binding to a particular 
promoter, changing its specificity toward a different promoter, or even interacting with RNA 
polymerase while it is bound at a promoter sequence and preventing it from elongating a 
transcript.    
In the case of BPs, we wanted to discover whether gp33103 could interact with RNA 
polymerase at OR within the PR promoter.  We started by purifying the mycobacterial RNA 
polymerase and then performed binding assays using gp33103 and RNA polymerase on the 33-34 
intergenic region.   
4.6.1 Purification of RNA polymerase 
The Burgess lab kindly gifted us some of their monoclonal antibodies recognizing 
bacterial RNA polymerase.  Polyol responsiveness means that the monoclonal antibodies bind 
tightly, but allow easy elution so that you can pull proteins down in complex during 
immunoaffinity chromatography.  This polyol responsive antibody binds to the beta flap tip helix 
of the beta subunit of bacterial RNAP’s and this is one of the major binding sites of SigA to the 
core enzyme (125, 180, 183-187, 196).  Therefore, this style of purification will only bring down 
the core RNA polymerase, not the holoenzyme.  So we had to purify the mycobacterial SigA 
sigma factor and reconstitute the holoenzyme.   
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4.6.1.1 Purification of M. smegmatis RNA polymerase core enzyme 
The Burgess lab sent us a small sample of their monoclonal antibodies that broadly 
recognize bacterial RNA polymerase beta (8RB13) and alpha (4RA2) subunits (197, 198).  The 
first thing we had to do was make sure that their antibodies recognized the M. smegmatis RNA 
polymerase subunits.  To do this, we performed a Western blot on a M. smegmatis mc2155 whole 
cell lysate next to an E. coli positive control whole cell lysate (Figure 39).  Both antibodies 
recognized the M. smegmatis RNA polymerase subunits, so we proceeded with the purification 
as described in section 4.2.4.1.   
 
 
Figure 39 - Western blots confirming 8RB13 and 4RA2 antibodies 
Western blots showing the (A) beta (8RB13) and (B) alpha (4RA2) RNA polymerase subunits of 
E. coli and M. smegmatis.   
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The purification was successful, although the antibodies pulled down an unidentified 
contaminant (Figure 40A).  Western blots of the purified M. smegmatis RNA polymerase 
showed that all of the correct subunits are present (Figure 40B), so we proceeded with 
purification of SigA.   
 
Figure 40 - Purification of M. smegmatis RNA polymerase 
(A) Shows an SDS PAGE gel of the M. smegmatis RNA polymerase purification.  (B) Shows 
Western blot confirmation of beta and alpha subunits in the purified pooled fractions.   
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4.6.1.2 Purification of M. smegmatis SigA 
His-tagged SigA was insoluble in the first two strains used to overexpress the protein, so we 
screened six new strains to try to find one that expresses soluble SigA (Figure 41A).  Since the 
band we presumed to be SigA ran higher than expected on an SDS PAGE gel (70kDa vs. 55kDa 
MW), we performed Western blots on the soluble lysates from each strain with an anti-Sigma 
factor antibody from the Burgess lab (2G10) (Figure 41B), and when those results were 
inconclusive, we performed a Western blots using an anti-His antibody (Invitrogen) (Figure 
41B).  We chose to continue with the RIL strain to perform a full-scale purification.   
 
Figure 41 - Purification of M. smegmatis SigA protein 
(A) The M. smegmatis SigA protein was overexpressed in multiple overexpression strains but it 
was unclear whether SigA was present.  (B) Western blots confirm the presence of SigA with a 
2G10 anti-sigma 70 antibody as well as an anti-His antibody to recognize the His-tag these 
proteins were expressed with.    
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To reconstitute the M. smegmatis RNA polymerase holoenzyme we mixed purified SigA 
and RNA polymerase core enzyme in a 10:1 ratio.   
4.6.2 Binding Assays with M. smegmatis RNA polymerase and gp3103 
We performed EMSAs with RNA polymerase and gp33103 on the 33-34 intergenic region 
substrate according to the protocol described in section 2.2.2 (Figure 42).  We started by adding 
RNA polymerase and gp33103 alone to determine their binding profiles, and then mixed RNA 
polymerase and gp33103 in different molar ratios. RNA polymerase by itself did not cause an 
upward shift on the gel indicating that it does not bind the promoter DNA (Figure 42).  This 
could either be because the RNA polymerase is not active, or because the RNA polymerase 
complex is too big to enter the gel matrix.  It is evident that some radiolabelled DNA is retained 
in the well, indicating that something is holding it there and presumably that is where the RNA 
polymerase complex is.   
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Figure 42 - RNA polymerase and gp33103 binding to the 33-34 intergenic region 
EMSA showing the binding profiles of RNA polymerase, gp33103, and both together.  RNA 
polymerase was unable to bind DNA in this assay.   
 
Gp33103 does bind DNA, but with the addition of RNAP there is no difference in 
gp33103’s binding profile (Figure 42).  Again the DNA trapped in the well indicates that perhaps 
the RNA polymerase complex is too large to fit through the gel matrix.   
We also performed the binding assays on the other intergenic regions with the same 




Figure 43 - RNA polymerase and gp33103 binding to othe rintergenic regions across the BPs genome 
EMSAs showing the binding profiles of RNA polymerase, gp33103, and both together to various 
intergenic regions across the BPs genome.  RNA polymerase was unable to bind DNA in this 
assay.  Gp33103 protein concentrations are 5.4µM or 16µM.  Asterisks mark lanes where a higher 
concentration of gp33103 was used.    
 
We decided to perform a binding assay on an agarose gel rather than a 5% native 
polyacrylamide gel to create a larger gel matrix through which RNA polymerase could migrate 




Figure 44 - RNA polymerase and gp33103 binding within the PR and Phsp60 promoters 
RNA polymerase and gp33103 were incubated with plasmid DNA containing the PR and Phsp60 
promoters as indicated.  RNA polymerase faintly binds DNA in this assay, and gp33103 seems to 
increase gp33103 binding, suggesting an interaction between the proteins.   
 
 
So we repeated the binding assay using a 1% agarose gel.  This gel is ethidium bromide 
stained and therefore no competitor DNA was added to prevent non-specific binding, because it 
would show up on the gel.  The substrates used in this assay are plasmids containing either PR or 
Phsp60 upstream of an mCherry reporter gene, because the M. smegmatis RNA polymerase has a 
dependence on supercoiling to work, so perhaps that is why the assay did not work in previous 
gels with linear substrates (199).  The results show that in both cases, RNA polymerase is able to 
bind DNA, at least slightly, and there is a small decrease in mobility of the PR substrate when 
gp33103 is added (Figure 44).    
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The results indicate that perhaps RNA polymerase and gp33103 do interact, because when 
OR is present (in the PR substrate) and gp33103 is added to the RNA polymerase complex, a 
higher shift occurs than with RNA polymerase alone.  However it is a smaller shift that we 
would anticipate for a huge holoenzyme binding to a DNA substrate, so these results are not 
definitive and need to be repeated. 
4.7 DISCUSSION 
In this section we show that gp33103 does not form inter-DNA bridges, but instead has the ability 
to bend DNA within the 33-34 intergenic region, likely within OR.  It cannot form a DNA bend 
when OR-R is by itself, however it does seem to bend DNA when two half sites are present on the 
same DNA substrate.  It would be informative to put two 12bp sites with varying spacer regions 
into the pBend2 plasmid and compare their abilities to bend DNA.  It would be interesting to see 
if there is a difference in, not just ability to bend, but also in the angles of DNA-bending.  It 
would also be informative to repeat the bending assay with the other BPs operators to determine 
if gp33103 bends at those sites and if it does, if it bends with a similar angle as in the 33-34 
intergenic region.   
 Gp33103 also may have an ability to interact with the M. smegmatis RNA 
polymerase as indicated by the small shift in a binding assay.  However more experiments need 
to be done to determine if this is the case, and if there is an interaction, the nature of the 




5.0  CONCLUSIONS AND FUTURE PROSPECTIVES  
We have described here the unusual binding properties of the repressor encoded by 
mycobacteriophage BPs.  The repressor is non-canonical in that it is encoded in two forms, a 
virally-encoded product 136-residues long (gp33136), and prophage-encoded version (gp33103) 
that is 33 residues shorter because the site where site-specific recombination works during 
integration (attP) is located within the gene 33 open reading frame.  The two proteins bind 
similarly to a DNA substrate containing the regulatory intergenic between genes 33 and 34, but 
the binding pattern is complex with multiple protein-DNA complexes observed (Figures 3, 4).   
BPs gp33103 binds to a total of six operators (O6, O27, ORep, OR, O55, O61) within the BPs 
genome, all of which are situated over promoters (P6, Prep, PR, P55, P61), except P27, for which the 
promoter sequences are not confidently predicted (Figures 5, 24-29).  The simplest explanation 
for DNA recognition is that each site contains two half sites, one of which corresponds closely to 
the palindrome 5’-CGACATATGTCG, and the other which is related to it but has some or many 
sequence departures.  Gp33103 probably occupies each of the full sites as a tetramer because this 
is the predominant and homogenous form observed in solution (Figure 8, 9), although it is also 
possible that each full site is occupied by two tetramers.  Occupancy as a tetramer is an unusual 
feature, although other phage repressors can form DNA loops involving tetrameric interactions 
(79).  However, at least with the substrates used here, there is no evidence of simultaneous 
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occupancy of all four protomers within a tetramer, and the significance of the stoichiometry 
remains unclear.  
Another unusual feature of gp33103 is the apparent ability of gp33103 to bind to sites in 
which different distances separate the two putative half sites (Figure 36, 38), although this is not 
unprecedented and is also seen in transposon resolvases (200).  There are clearly some 
cooperative interactions that enhance binding affinity for gp33103, even though for many 
substrates these are of slight magnitudes.   
Our first model of how gp33103 could be binding involves a tetramer binding to each half 
site and interacting to create a DNA bend.  The depiction in Figure 45A shows a hypothetical 
explanation for what each of the complexes in the gp33103 binding profile mean under the 
premise of this model.  This model could also be applied to dimers binding to each half site 
(Figure 45A).  In both cases, two protomers bind to each half site and interact to bend DNA 
when the inter-site spacing is correct.   
Our second model postulates one protmer binding to each half site.  In this model, a 
dimer would bind to the full site and the spacing between half sites determines whether or not 
both protomers can interact with and bend DNA.  This also applies for a tetramer binding to a 
full site as illustrated in Figure 45B.   
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Figure 45 - Models of gp33103 binidng (A) Our first model for gp33103 binding with two protomers binding each half site.  (B) Our second model with one protomer binding at each half site.   
 103 
To conclusively determine the actual stoichiometries of protein binding to each operator, 
there are a variety of experiments that can be performed.  One approach is to create Ferguson 
plots with relative mobility of substrates vs. the concentration of acrylamide to deduce the 
absolute molecular weight of the complexes being formed.  Another method is to perform an 
experiment whereby gp33103 would be synthesized with 35S-methionine incorporated and the 
counts per protomer could be calculated.  Using known quantities and counts of 32P-labeled 
probe would allow the ratio of 35S to 32P counts to be calculated and the stoichiometries of 
protein per DNA molecule could be surmised.  This would require very careful calibration and 
may be time consuming and difficult to accomplish.  An easier and faster experiment would be 
to crosslink the proteins to DNA during the binding reaction and then run the samples on a 
denaturing SDS PAGE gel.  If the protein binds as a monomer, a ladder-like pattern will be seen, 
however if the protein does indeed bind as a tetramer, a step-like pattern will occur.  An 
alternative approach to the size-exclusion chromatography used is to perform sedimentation 
equilibrium to isolate protein complexes.  If multiple complexes are formed, this can help 
determine what intermediate binding profiles are composed of.  Also, mass spectrometry, surface 
plasmon resonance (201) or fluorescence anisotropy could be used (202).   
Alignment of the six putative DNA binding sites (O6, O27, ORep, OR, O55, and O61) shows 
the juxtaposition of the half sites within each operator (Figure 46).  In four of the sites (O6, O27, 
OR, and O55), one half site contains the 12 bp palindrome (O6-L, O27-R, OR-R, and O55-L) and is 
easily recognizable, and the other half sites (O6-R, O27-L, OR-L, and O55-R) contain sequence 
departures at two or more positions (Figure 46).  At O61, both half sites have sequence 
departures from the consensus (two in O61-R and five in O61-L) although gp33103 binds with 
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similar affinity as it does to O6 and O55 (Figure 46).  A half-site alignment shows that the 12bp 
palindrome is indeed the consensus sequence for each half-site (Figure 47).   
 
 
Figure 46 - Full site alignment for BPs operators 
 
Figure 47 - BPs operator half site alignment 
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With most half-sites, more than two base pair departures from the consensus do not 
support gp33103 binding, but OR is peculiar in that the OR-L half site is only distantly related, 
although gp33103 clearly binds to it, even in the absence of OR-R (Figures 18, 19, 21). OR-L is 
spaced five bases away from OR-R, which is similar to the geometries of O6, O27, and O61 (Figure 
46). We also note that position eight of this proposed OR-L is part of the PR -35 motif, and 
substitution with a G base both increases promoter activity, but also reduces the efficiency of 
repression (102), consistent with a role for OR-L in binding and regulation.  
The sequences of the ORep half sites are the most divergent, and the best alignment 
suggests that ORep-L and ORep-R have eight and seven positions conserved respectively (Figure 
46), spaced eight bases apart (Figure 47), similarly to O55. DNase I footprinting is consistent 
with binding to these sites, and complexes are observed with the small substrate tested that 
contains the complete sequence (Mt10, Figure 21). At least at higher protein concentrations, 
binding of gp33103 to the 33-34 intergenic regions is expected to involve occupancy of both OR 
and ORep although this likely involves multiple gp33103 tetramers, as there is not evidence of 
protein-mediated bridging, or loop formation. If loop formation did occur, there would probably 
need to be another DNA-bending protein involved, since ORep and OR are only ~150bp apart and 
our evidence suggests that gp33103 can only bend DNA up to 48°.  Due to the low binding 
affinity of gp33103 to ORep, it is possible that this operator is only bound when protein levels get 
too high in the lysogen and that this operator functions to regulate repressor levels during 
lysogeny, similarly to OR3 in lambda (69, 77).   
Despite the complexity of the binding profile of gp33103 to the 33-34 intergenic region, 
formation of properly configured complexes is necessary for normal repression in a lysogen. BPs 
mutants with repressor-insensitive phenotypes that have mutations mapping to the 33-34 
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intergenic region demonstrate the importance of this sequence and the ability of gp33103 to bind 
to it (Figures 30, 31). Loss of normal repression does not closely correlate with large changes in 
binding affinity, but the relatively subtle sequence changes give rise to altered configurations that 
interfere with repression. This notwithstanding, some DNA substrates of the repressor-
insensitive mutants have binding patterns that are more consistent with binding of monomers or 
dimers (e.g. 127b, Figure 31), and it is unclear what determines this behavior. 
While inter-site spacing seems to have an effect on the gp33103 binding profile in vitro, a 
logical question is to ask whether the spacing between half sites is important in vivo.  We know 
that narrowing the space between OR half sites leads to a decrease in repression in a lysogen 
based on Lauren Oldfield’s fluorescent reporter experiments with mutated versions of PR (Figure 
37).  In order to test whether this spacing is important for all of the phages in vivo, BRED can be 
used to insert and delete base pairs between operator half sites in all BPs operators.  For 
example, we can ask if changing the spacing between O27 or O6 half sites from 5 to 8 changes the 
phage’s ability to enter lysogeny or maintain the lysogenic state.  We can similarly examine 
whether changing the spacing of O55 and ORep from 8 to 5 base pairs changes the gene expression 
in a lysogen or increases lysogenization efficiency.  Alternatively, fluorescent reporter assays can 
be done with the promoters containing the above-mentioned operators and spacing can be tested 
in the same manner as PR and OR.   
It is unknown whether gp33103 has the ability to interfere with transcript elongation, 
however an elegant design to test this would be to create fluorescent reporter assays with a 
promoter unregulated by gp33103 (such as Phsp60) and insert two full 12bp palindromes spaced 
5bp apart downstream of the promoter and upstream of the reporter gene, and then express this 
construct in wild type M. smegmatis as a control, and into a BPs lysogen to see if the reporter 
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gene is repressed by gp33103 due to the presence of an operator (83).  If it did exert an effect over 
transcription elongation, this “stoperator” function may be used at any of the operators found in 
the BPs genome, but would probably be most likely used in O61, where the P61 promoter is not 
downregulated in a lysogen in fluorescent reporter assays.  Binding to O61 may prevent the RNA 
polymerase from continuing to elongate the P55 or P58 operon transcripts (103).  It could also be 
used at O27 to prevent any possible read-through transcription from expressing the lysis gene 
cassette.   
Gp33103 may also interact with the mycobacterial RNA polymerase, however the assays 
performed thus far have not shown any conclusive evidence for this interaction (Figures 42, 43, 
44).  The next step to check if gp33103 and RNA polymerase truly interact, is to perform a pull-
down assay.  We have constructed a vector with an HA-tagged M. smegmatis rpoA gene placed 
downstream of an Hsp60 constitutive promoter (pVMV36).  When transformed into wild type M. 
smegmatis and a BPs lysogen, the cell lysates containing RNA polymerase with tagged alpha 
subunits can be used in immunoaffinity chromatography with an anti-HA antibody to pull down 
the RNA polymerase complex, along with anything it interacts with (203).  Mass spectrometry 
can reveal if the pull-down results from the lysogen include gp33103.  This technique could also 
be used to identify any other phage proteins that interact with RNA polymerase, or used to 
determine the unidentified repressors of other phages by performing co-immunoprecipitation 
with this system in other phage lysogens.   
The system of integration-dependent immunity seen in BPs and other phages offers a 
different perspective on phage life style decision making than seen in phage lambda and its 
relatives, and may represent an ancestral state for temperate phages (204). In light of this, it is 
not surprising that the repressor has non-canonical binding properties including tetramerization 
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and binding to dispersed sites in the phage genome. Because the repressor can be expressed in 
two forms that differ in their C-termini, this raises the possibility that the virally-encoded product 
gp33136 forms mixed tetramers with the shorter protein (gp33103) and exerts a dominant effect. 
Thus the observed tetramerization and DNA binding profiles may play roles in modulating the 
overall genetic switch in these phages. 
The work done in this study has shed light on the mechanism action of a new phage 
repressor.  This information has helped uncover how a novel type of integration-dependent 




OTHER PHAGE REPRESSORS THAT CONFER INTEGRATION-DEPENDENT 
IMMUNITY 
A.1 INTRODUCTION 
  Integration-dependent immunity systems have been found on phages from different 
clusters as described in Broussard et al, 2013.  Mycobacteriophage Brujita (Cluster I1) and 
Charlie (Cluster N) immunity cassettes have a similar structure to the one in BPs (Cluster G).  
They include an Integrase gene and a Repressor gene amplified leftward from a Prep-like 
promoter, and a rightward facing PR-like promoter, which transcribes an early lytic operon.  
Because of this, we initially started this project by working with the repressors of all three 
representative phages, not just BPs.  In this appendix we describe the purification of the long and 
short forms of the Brujita and Charlie repressors and the assays done to show that all of these 
repressors bind to their respective primary regulatory intergenic regions (similar to the BPs 33-
34 intergenic region).   
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A.2 MATERIALS AND METHODS 
 
A.2.1 Plasmid Construction and Protein Purification 
The short and long versions of the mycobacteriophage Brujita and Charlie repressor 
genes (Gene 34 gp34101 & gp34129 and gene 35 gp35103 & gp35124, respectively) were cloned into 
a pLC3 vector that expresses the genes with an N-terminal maltose binding protein fusion.  The 
resulting plasmids, pVMV18 (Brujita gp34101), pVMV19 ( Brujita gp34129), pVMV16 (Charlie 
gp35103), and pVMV17 (Charlie gp35124),  were transformed into BL21(DE3)pLysS chemically 
competent E. coli cells (Invitrogen) and confirmed colonies were inoculated into LB/Kan/CM 
media to saturation.  The saturated cultures were used to inoculate new cultures at 0.01 OD600 
and once cultures reached an optical density of OD600=0.4-0.6, protein expression was induced 
with addition of 1mM IPTG and incubation at 37°C with shaking for 3 hours.  Cells were 
harvested using centrifugation and pellets were resuspended in 5mL/g with Lysis Buffer 
(300mM NaCl, 5% Glycerol, 50mM Tris, pH8.0).  Resuspended cell pellets were thawed, 
incubated with protease inhibitors, and lysed using a VirSonic Sonicator (ten 10s pulses at 20-
30% output with 30s of ice in between pulses).  Lysates were cleared using centrifugation and 
the resulting soluble lysate was incubated with equilibrated Amylose resin for 2hrs at 4°C.  Resin 
was poured over a disposable BioRad column and washed with Lysis Buffer.  Bound protein was 
eluted using Lysis Buffer + 0.25% Maltose.  Eluted fractions containing the purified fusion 
protein were pooled and dialyzed overnight with TEV Protease (from the VanDemark Lab) to 
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cleave the MBP tag off of the proteins.  The resulting partial purification was used in Binding 
assays.   
A.2.2 DNA binding assays 
EMSAs were performed as previously described in section 2.2.3.  Substrates were PCR 
amplified from the lysates of the respective mycobacteriophages (Lysates acquired from Gregory 
Broussard).   
A.3 RESULTS 
A.3.1 Brujita gp34 binds to the 34-35 intergenic region 
The Brujita gp34101 and gp34129 were used in EMSAs with a 34-35 intergenic region probe.  As 
expected, both the long and short forms of the Brujita repressor are able to bind the 34-35 
intergenic region substrate (Figure 48A).  The binding is very modest, and only occurs at the 
highest protein concentrations, and no binding assay has been done on a non-specific DNA 
substrate for reference, however the concentrations of partially purified Brujita repressor used 




Figure 48 - Brujita and Charlie repressors bind to their respective regulatory intergenic regions 
 
A.3.2 Charlie’s gp35 binds to the 35-36 intergenic region and not a non-specific 
contaminant 
The Charlie repressors gp35103 and gp35124 were also used in EMSAs to the regulatory 
35-36 intergenic region.  In this assay, a Charlie phage lysate was used as a template for PCR 
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purification.  This lysate was later confirmed to have a contaminating phage present (Gregory 
Broussard) and therefore there the contaminating band present in the unbound DNA is likely a 
non-specific substrate that amplified along with the 35-36 intergenic region (Figure 48B).  With 
this in mind, Charlie’s repressors each bind to one substrate (presumably the 35-36 intergenic 
region) and not to the other (Figure 48B).   
 
A.3.3 BPs gp33103 is able to bind the Brujita 34-35 intergenic region, but not Charlie’s 35-
36 intergenic region 
In the Brujita 33-34 intergenic region we discovered a 12bp sequence that diverges from 
the BPs OR-R by 4 base pairs.  We wanted to test if the BPs repressor was able to bind to this 
region, even though immunity assays have shown that Brujita can grow lytically on a BPs 
lysogen as well as in strains expressing the active form of the BPs repressor (97).  The BPs 
repressor was used in binding assays with the Brujita and Charlie primary regulatory intergenic 
regions (Figure 49).  Gp33103 was able to bind to the Brujita 34-35 intergenic region, but not to 




Figure 49 - gp33103 binds to the Brujita 34-35 intergenic region 
A.4 DISCUSSION 
Further analysis needs to be done to prove that the Charlie and Brujita repressors bind 
specifically to their respective primary regulatory regions (Figure 48).  Some experiments that 
can be done initially include fully purifying the repressors to get accurate protein concentrations 
and convincingly show that the binding profiles seen belong to the respective proteins and not to 
a contaminant in the protein preparations.  Also, performing binding assays with non-specific 
DNA susbtrates to show that these proteins are binding specifically would be useful.   
The most confident results we saw came from mycobacteriophage Charlie, because the 
presence of an unanticipated non-specific band (resulting from an impure phage lysate being 
used in PCR) shows that the binding of the Charlie repressor is specific (Figure 48B).  The 
binding profile of these proteins contain multiple complexes, just as the BPs repressors create 
multiple complexes with its 33-34 intergenic region.    
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Interstingly, although BPs and Brujita’s repressors do not confer immunity to the other 
phage, the BPs repressor is able to bind to Brujita’s regulatory 34-35 intergenic region (Figure 
49).  The Brujita 34-35 intergenic region contains a 12bp sequence with four base departures 
from the OR-R palindrome, and presumable this is where gp33103 binds.  Two reasons for gp33103 
being unable to exert an effect include no second half site being located nearby, and the half-site 
not being situated over the PR promoter.  The Charlie and Brujita repressor proteins could be 
used to supplement the data gathered on the BPs gp33103 to create a more convincing argument 
for the function of this new class of repressor in all of the clusters this integration-dependent 
immunity system is found.   
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APPENDIX B 
OTHER PROTEINS INVOLVED IN CONFERRING IMMUNITY IN BPS LYSOGENS 
B.1 INTRODUCTION 
The first gene of an early lytic BPs operon, gp34, is predicted to have a Cro-like function that 
antagonizes the function of gp33.  The evidence for this was presented by Broussard et. al. in 
2013.  They created strains expressing gp34 and tested the ability of BPs to infect these strains.  
A marked decrease of lysogenization frequency occurred, leading to the hypothesis that gp34 is a 
cro-like protein.  Gp34 is small (81aa) and has a predicted helix-turn-helix DNA binding motif.  
If this protein has a cro-like function, it should compete with gp33103 to bind the appropriate sites 
on the 33-34 intergenic region to reduce Prep activity.    In this appendix we describe the 
attempted purification of BPs gp34 and the binding assays done with a partially purified protein 
preparation.   
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B.2 MATERIALS AND METHODS 
B.2.1 Plasmid construction and protein purification 
The BPs gene 34 was cloned into a pLC3 vector that expresses the gene with a maltose 
binding protein fusion using directional cloning with NdeI and HindIII restriction enzyme sites.  
The resulting plasmid, pVMV6, was transformed into BL21(DE3)pLysS and confirmed colonies 
were inoculated into 5mL LB/Kan/CM media to saturation.  The saturated cultures were used to 
inoculate new cultures at 10% and once cultures reached an optical density of OD600=0.4-0.6, 
protein expression was induced with addition of 1mM IPTG and incubation at 37°C with shaking 
for 3 hours.  Cells were harvested using centrifugation and pellets were resuspended in 5mL/g 
with Lysis Buffer (300mM NaCl, 5% Glycerol, 50mM Tris, pH8.0).  Resuspended cell pellets 
were thawed, incubated with protease inhibitors, and lysed using a VirSonic Sonicator (ten 10s 
pulses at 20-30% output with 30s of ice in between pulses).  Lysates were cleared using 
centrifugation and the resulting soluble lysate was incubated with equilibrated Amylose resin for 
2hrs at 4°C.  Resin was poured over a disposable BioRad column and washed with Lysis Buffer.  
Bound protein was eluted using Lysis Buffer + 0.25% Maltose.  Eluted fractions containing the 
purified fusion protein were pooled and dialyzed overnight with TEV Protease to cleave the 
MBP tag off of the gp34 proteins.  The cleaved protein mixture was run over a Nickel column to 
remove the His-tagged TEV protease and His-tagged MBP tag, however the tag and protease 
eluted with gp34 and we were unable to separate gp34 from the other proteins.  This partially 
purified protein was used in DNA binding assays as described below.    
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B.2.2 DNA Binding assays 
EMSAs were performed as previously described in section 2.2.3.  Substrates were PCR 
amplified from a lysates mycobacteriophage BPs (Lysates acquired from Gregory Broussard).  
B.3 RESULTS 
We used a partially purified gp34 protein preparation to do binding assays on various 
susbtrates (Figure 50A).  Cro did not bind to a non-specific substrate or to a substrate containing 
the intergenic region between genes 32-33 which was initially hypothesized to contain a cryptic 
PInt promoter (although that theory was disproven by Broussard et al., 2013) (Figure 50B).   Cro 
does bind DNA within the 33-34 intergenic region, however it looks like it binds with an 
extremely low affinity (Figure 50B).  Without knowing the concentration of the protein in the 




Figure 50 – gp34 purification and pinding to BPs 33-34 intergenic region 
 
Reasons for why we believe that the small shift seen indicates that gp34 truly does bind 
to the 33-34 intergenic region (Figure 50B) include the low proportion of gp34 in the partially 
purified preparation leading to a low concentration of protein that is not present in enough 
quanitities to see its full binding profile.  Also, the fact that gp34 does not create any shifts when 
non-specific DNA or DNA without operator sites are used as probes indicates that the shift seen 
when gp34 is mixed with the 33-34 intergenic region reflects a real protein-DNA interaction.  
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B.4 DISCUSSION 
The BPs gp34 may have a cro-like function in the integration-dependent immunity genetic 
switches, however there is not currently enough evidence to convincingly report this.  Showing 
that gp34 binds to the intergenic region where gp33103 is known to bind is a step in the right 
direction, but these results need to be solidified.  To do this, gp34 must be fully purified and 
concentrated to a useable concentration.  BPs gp33103 binds with a Kd of ~2µM, so it is logical to 
assume that gp34 binds to DNA with a similar binding affinity.  If it bound with a higher affinity 
than gp33103, lysogeny would never occur.   
It would also be useful to show where the gp34 protein binds within the 33-34 intergenic 
region to see if it competes with gp33103 for binding sites.  To do this, DNase I footprinting could 
be used.  Once the gp34 binding sites are identified, conjectures can be made as to how the 
proteins interact and compete for binding.  The characterization of gp34’s binding sites and 
elucidation of the nature of its interaction with gp33103 would provide valuable knowledge about 




BPS GP33103 N-TERMINAL SIX RESIDUES ARE IMPORTANT FOR DNA BINDING 
C.1 INTRODUCTION 
Before the transcription start site of Prep was confirmed and the promoter was known to be 
leaderless, gene 33 had a different predicted start site.  This gene was 130 aa long instead of 136 
and the expressed protein (gp33130) was missing its N-terminal 6 amino acids ([M]SQAFD).  We 
purified this protein using the incorrect start site located 18 base pairs into the now-confirmed 
correct open reading frame and the short, “active” form of the protein, gp3397, was unable to 
bind DNA.   
It is known that without its first seven residues ([M]STKKKP), the binding affinity of 
lambda cI decreases 8000-fold because the N-terminus comprises a flexible arm that wraps 
around the DNA helix and assists in binding specificity (45, 205).  This appendix examines the 
evidence collected that shows that the N-terminal residues of gp33103 are important for binding.   
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C.2 MATERIALS AND METHODS 
C.2.1 Plasmid construction and protein purification 
The gp3397 gene was PCR amplified from a BPs lysate using primers 5’-CAA TCG CCC ATA 
TGT CGC AAG CAT TCG -3’ and 5’-CAA TCG CCC ATA TGT CGC AAG CAT TCG -3’, 
which amplified the gene with a NdeI recognition site at the 5’ end of the gene and a HindIII 
recognition site at the 3’ end.  The PCR product was digested with NdeI and HindIII fermentas 
fast digest enzymes and ligated into a maltose-binding fusion vector (pLC3) that was linearized 
with NdeI and HindIII sites for directional cloning, creating the plasmid pVMV1. Confirmed 
pVMV1 was transformed into BL21(DE3)star chemically competent cells (Invitrogen) and 
grown until cultures reached an OD600 of 0.4-0.6. Protein expression was induced with 1 mM 
IPTG at 17°C overnight. Cells were pelleted and frozen at -80°C. Thawed cell pellets were 
resuspended in 5mL per gram of Lysis Buffer (50 mM Tris pH 8.0, 500 mM NaCl, 8% glycerol, 
1 mM EDTA and 1 mM β-mercaptoethanol) and lysed in 200 mL fractions by sonicating 10 
times for 10 sec at 30% output with 30 sec of cooling on ice in between bursts. Pooled cell 
lysates were cleared by centrifugation at 30,000 x g for 40 min at 4°C. Fusion proteins were 
extracted from soluble cell lysates using amylose resin affinity chromatography (Invitrogen) and 
the MBP tag was cleaved from the proteins of interest with TEV protease during overnight 
dialysis at 4°C.  MBP and TEV protease contain C-terminal His tags and were removed from the 
gp3397 proteins using nickel affinity chromatography. The flow through containing pure gp3397 
proteins was dialyzed into a storage buffer (50 mM Tris pH 8.0, 500 mM NaCl, 50% glycerol, 1 
mM EDTA, 1 mM BME) and stored at -20°C.   
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C.2.2 DNA Binding Assays 
EMSAs were performed as previously described in section 2.2.3.  Substrates were PCR 
amplified from a BPs lysate.  Lysates were acquired with permission from Gregory Broussard.  
C.3 RESULTS 
C.3.1 Gp3397 does not bind DNA, but gp33103 does 
Before we knew that gp33103 was expressed from a leaderless transcript, we purified a shorter 
form, gp3397, using an incorrect start site located 18 base pairs into the correct open reading 
frame.  This form of the protein was unable to bind DNA (Figure 51) even at its highest 
concentration, 5µM.  The most obvious explanation for these results is that the missing N-
terminal amino acids are important for binding activity, although an alternative explanation is 
that the low amount of protein, even at the highest concentrations, may not be enough to see 
binding.  We know that the binding affinity of gp33103 is very low (~2µM) and 5µM may not be 




Figure 51 - gp3397 does not bind DNA 
EMSAs done with gp3397 show that the protein only binds DNA very faintly at the highest 
concentration of protein.   
C.3.2 Clear-plaque and repressor-insensitive mutations map to N-terminal gp33103 
residues 
Some repressor-insensitive mutants also suggest that the region between the N-terminus of gp33 
and its helix-turn-helix DNA binding motif is important for binding.  Broussard et. Al isolated 13 
repressor-insensitive and clear plaque mutants that had mutations mapping within the repressor 
gene.  Five of these were located between the N-terminus and the predicted helix-turn-helix 
DNA binding motif (Figure 52).  One of these was a substitution of the 6th residue (D6G).  
Another was an arginine to glycine substitution at the 14th amino acid.  Interestingly, three 
mutants were isolated that had amino acid substitutions in the 11th residue (P11L, P11S, P11S), 




Figure 52 - Repressor insensitive BPs mutants with mutations in the N-terminus of gp33 
Diagram shows an arrow as a representation of the repressor gene, white boxes show the helix 
turn helix motif and the attP core is underlined.  Mutations are indicated with black lined.   
 
C.4 DISCUSSION 
The N-terminus of the BPs repressor protein is important for DNA binding.  Removal of the 
protein’s six N-terminal amino acids led to a binding-deficient phenotype at the concentrations 
used.  To explore this result in more detail, the next step in this experiment would be to 
determine if the protein is truly unable to bind, or if it just binds at a very reduced binging 
affinity. Since lambad cI’s binding is reduced 8,000-fold when it’s first 7 residues are missing 
(206, 207), perhaps gp3397 also has a very reduced binding affinity.  To test this, a higher 
concentration of pure protein will be needed and binding assays will need to be done with this 
more concentrated protein preparation to see if gp3397 binds when present at higher 
concentrations.  It would be interesting to see, if gp3397 does bind at higher concentrations, if the 
specificity of binding is affected by removal of the 6 N-terminal residues, if gp3397 can still bend 
DNA, and if the protein still retains its ability to tetramerize.  DNase I footprinting, DNA 
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bending assays, and size exclusion chromatography could be utilized to look at these properties 
in greater detail.   
Results from clear plaque and repressor-insensitive mutants showed that the residues 
between the N-terminus and helix-turn-helix binding motif are important, especially the 11th 
residue.  Whether this proline makes up part of a flexible arm that helps in DNA recognition like 
in the lambda cI protein (206, 208-210) or a different aspect of protein-DNA recognition, or if 
it’s somehow involved in a direct interaction with another protein, such as a subunit of RNA 
polymerase (178, 179), or even if it’s involved in something like facilitating tetramerization of 
the protein (211), it seems to have an important role because without it, gp33 does not function 




CONCENTRATION OF GP33103 IN A BPS LYSOGEN 
D.1 INTRODUCTION 
An interesting question from the perspective of the BPs genetic switch as a whole is what the 
concentration of gp33103 is in a BPs lysogen of Mycobcaterium smegmatis.  We would predict 
that the levels of protein needed to maintain lysogeny would be higher than most other phages 
considering the low binding affinity that gp33103 has for its operator sites. We attempted to 
determine the concentration of the BPs repressor in a lysogen through Western blot assays.  This 
appendix details the experiments done to try to quantify the levels of go33103 in a BPs lysogen.   
D.2 MATERIALS AND METHODS 
D.2.1 Creation of polyclonal antibodies against gp33103 
Polyclonal antibodies to gp33103 were created through the Pocono Rabbit Farm & lab.  We sent 
5mg of pure gp33103 to the facility and through the 28-day Mighty Quick Protocol with one final 
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boost from a gel slice on week 29, two rabbits (28951 & 28952) were immunized with the 
protein three times and bled every two weeks.  Titermax was used as an adjuvant because the 
standard Freud’s Complete adjuvant contains M. tuberculosis proteins that can be cross-reactive 
with mycobacteriophage proteins.  Serum from the bleeds was collected and sent back to us for 
analysis.  Western Blots showed that antibodies from all the bleeds worked and the final 
exsanguination was collected and sent to us.   Antibody aliquots were stored at -80°C.   
D.2.2 Growing M. smegmatis mc2155 
7H10 agar (Difco) media plates supplemented with carbenicilin and cyclohexamide were 
streaked with the lab strain of M. smegmatis mc2155 (212) as well as a BPs lysogen of M. 
smegmatis mc2155 acquired from Gregory W. Broussard, PhD.  Single colonies were picked into 
7H9 broth (Difco) supplemented with CB/CHX/ADC and Tween 80 according to standard 
practice and grown at 37°C overnight with shaking.   
D.2.3 Western blot analysis 
Western blots were performed as previously described (213).  Briefly, protein samples were run 
on an SDS polyacrylamide gel and transferred to a PVDF membrane (BioRad) using a BioRad 
wet transfer apparatus according to manufacturer recommendations.  The membrane was blocked 
with TBS + 5% milk for 1-3 hours, washed with TBST three times for 5min, probed with 
primary antibody in TBS + 5% BSA (28951 or 28952) at a 1:500 dilution for 30-60min, washed 
with TBST three times for 5min, and probed with anti-mouse AP-conjugated secondary antibody 
in TBS + 5% milk for 30min.  After two quick rinses with TBS, a BCIP/NBT Substrate Kit 
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(Invitrogen) was used to induce a colorimetric reaction from the secondary antibodies and 
presence or absence of probed protein was detected.  Blots were dried between sheets of filter 
paper and stored.   
Tris-Buffered Saline (TBS): 20mM Tris pH 7.5, 150mM NaCl 
TBS with Tween 20 (TBST): 20mM Tris pH 7.5, 150mM NaCl, 0.1% Tween20 
Transfer Buffer: 25mM Tris, 190mM Glycine, 20% methanol and pH to 8.3 
D.3 RESULTS 
D.3.1 Confirmation of BPs lysogen 
To confirm that the BPs lysogen was in fact a lysogen, and lysogeny assay was performed.  In 
this assay, a lawn of M. smegmatis mc2155 was plated on a 7H10 agar plate supplemented with 
CB/CHX.  The BPs lysogen was streaked on this lawn and the plate was incubated at 37°C for 
48 hours (Figure 53).  This showed cleared areas of the M. smegmatis lawn, indicating release of 
lytic BPs, as well as lysogenic colonies growing in the middle of the zones of clearing, which 
indicated that the culture is in fact a lysogen.  To prove that this was a BPs lysogen, a spot test 




Figure 53 - Confirmation of the BPs lysogen 
A BPs lysogen strain was streaked onto a lawn of wild type M. smegmatis mc2155 to look for 
areas of clearing due to phage release.  The strain tested is a confirmed lysogen.   
D.3.2 Detection of repressor in a lysogen lysate 
Purified gp33103 was sent to Pocono Rabbit Farm & Laboratory to create polyclonal rabbit 
antibodies that recognize the active BPs repressor, gp33103.  Western blots using the antibodies 
have shown specific recognition to gp33103 and not to negative control phage Bxb2 C-terminal 
domain (Figure 54B&C).  Probing the proteins in whole cell lysate of a Mycobacterium 
smegmatis BPs lysogen (which expresses gp33103 to maintain the prophage) with the anti-gp33103 
antibody to check native levels of repressor shows no bands in the lysogen corresponding to 
gp33103 (Figure 54A).  We looked up the concentration of CI repressor in a lambda lysogen (12) 
and used that as a template to determine the number of cells needed to get a detectable quantity 
of gp33103 (~50ng).  We used 1x109 cells in the lysogen preparation but we still did not detect 




Figure 54 - using an anti-gp33103 antibody to determine the concentration of repressor in a lysogen 
 
(A) Testing the 28951 anti-gp33103 antibody on a series of gp33103 dilutions.  (B) Testing the 
anti-gp33103 antibody on a BPs lysogen.  No gp33103 was detected.   
 
Gp33103 is an 11.2 kDa protein that typically runs at 14kDa on an SDS PAGE gel and the 
band in the lanes corresponding to the BPs lysogen and wild type M. smegmatis is approximately 
30 kDa.  This band is probably recognized because the protein sample sent to Pocono Rabbit 
Farm & Laboratory was not 100% pure and the co-purified contaminants could have affected 
antibody production.   
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D.4 DISCUSSION 
Our approach was to use custom-made polyclonal antibodies that recognize the BPs 
repressor in Western blots to detect gp33103 in a lysogen and compare that to known quantities of 
protein to roughly quantify the protein concentrations.  We were unsuccessful in detecting 
gp33103 in a lysogen.  This could be for a variety of reasons; either gp33103 is not present in high 
enough levels to meet the detection threshold of the antibodies, gp33103 could be insoluble and/or 
be unrecognizable by my antibody in the context of a whole cell lysate, or perhaps gp33103 has a 
very short half life and is rapidly degraded in the preparation stages before the blot is prepared.  
Even though the antibodies we created were not sensitive enough to detect gp33103 in a 
BPs lysogen, these results don’t necessarily mean that the in vitro work we have done does not 
pertain to biologically relevant actions of BPs.  It is known that bacteriophages localize to poles 
when they adsorb to a host cell during infection (215) and perhaps when lysogeny occurs, the 
repressor is localized to the area of the cell where the chromosome is situated, leading to a 
greater concentration in that area than in the cell as a whole.  
These antibodies can be useful in a variety of genetic experiments and can be used in the 
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